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ABSTRACT 
 
Sex Differences in the Anxiety Effects of Cannabinoids 
By  
Helen T. French 
 
Advisor: Vanya Quinones 
 
Aim: Anxiety disorders are twice as common among women, and those with anxiety disorders are 2-3 
times more likely to have a substance abuse disorder than the general populace. However, little data 
exists on the sexually dimorphic effects of cannabinoids. In male humans and rodents, low acute doses of 
cannabinoids are anxiolytic while high and/or chronic doses are anxiogenic. In the dose response curve 
(DRC), we examined whether the biphasic effects of cannabinoids observed in males are also present in 
females. In the CB1R antagonism study, CP55,940-induced CB1R activation was antagonized via the 
CB1R-selective antagonist rimonabant to test the hypothesis that sexually dimorphic CB1R activation 
underlies sex differences observed in response to CP55,940 administration.  
 
Methods: Male and female adult Wistar rats received 0, 0.001, 0.01, 0.075 or 0.125 mg/kg i.p. of the THC 
agonist CP55,940 in the DRC. Thirty minutes later, rodents were tested for 10 minutes in the elevated 
plus maze (EPM) and their behavior analyzed with Med Associates tracking software.  Western blot 
analysis assessed changes to p-DARPP-32 (Thr34), p-ERK, p-CREB and cFOS following sacrifice. In the 
CB1R antagonism study, rodents received 3.0 mg/kg of the CB1R antagonist rimonabant, followed thirty 
minutes later by 0.075 mg/kg i.p. CP55,940 and methods were thereafter as described for the DRC.  
 
Results: In the DRC, we found main effects of dose and sex on percent open arm time and percent open 
arm entries. Male manifested a bi-phasic, dose-dependent response as expected, while females had a 
dose-dependent anxiogenic reaction to CP55,940. Sex and dose effects were observed in multiple brain 
areas and proteins. The CB1R antagonism study demonstrated a potentiating effect of pretreatment with 
v 
 
the CB1R antagonist rimonabant on anxiety, but a restorative effect on locomotion. Dose and sex effects 
were observed for changes in protein expression in multiple brain regions.  
 
Conclusion: Sex differences were observed in the effect of CP55,940 on anxiogenic and anxiolytic 
responses, and in the effects of rimonabant. Although males showed biphasic dose dependent 
responses, females showed only an anxiogenic response to CP55,940. Further research is needed to 
understand the underlying mechanisms responsible for these differences.  
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I. INTRODUCTION 
1.1 Human Cannabis Use   
1.1.1 Statistics on Cannabis Use  
Cannabis use has been rising during the legalization of marijuana. To date, 26 states and Washington DC 
have legalized marijuana for medical use, and seven states allow recreational use. It is the most widely 
used (formerly) illicit drug in both the world and within the United States. It was consumed by 125 to 203 
million people worldwide in 2011, which is an annual prevalence rate of approximately 2.8-4.5% 
(UNODC, 2011). In the United States, there were 22.2 million current marijuana users (users in the past 
month) age 12 or older and the percent of current users was significantly higher in 2013 than in 2002 
(CBRHSQ, 2015). Daily or almost daily marijuana consumption (used on 20 or more days in the past 
month) has increased from 5.1 million persons in 2007 to 7.6 million persons in 2012 (Figure 1; SAMHSA, 
2012). Between 2001 and 2013 prevalence of marijuana use disorder increased from 1.5% to 2.9%. 
Interestingly however, the prevalence of marijuana use disorder among marijuana users decreased 
significantly from 2001-2002 (35.6%; SE, 1.37) to 2012-2013 (Wu et al., 2015).  Marijuana use is common 
among adolescents and young adults, and while the last decade saw a decline in use among this age 
bracket, marijuana consumption has increased among young people since 2007 (Figure 2, SAMHSA, 
2011). This increase corresponds to a diminishing perception of the risks associated with marijuana use 
(ISR, 2012).  
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Figure 1. Daily/Almost Daily Marijuana Use in the Past Year and Past Month among Persons Aged 12 or 
Older: 2002-2012 (Figure 1 was adapted from SAMHSA, 2012). 
  
 
 
 
Figure 2. Past Month Marijuana Use among Youths Aged 12 to 17, by Gender: 2002-2011 (Figure 2 was 
adapted from SAMHSA, 2011). 
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1.1.2 Positive Subjective Effects of Cannabis 
Individuals may use cannabis to improve their affect and/or alleviate the symptoms of their mental illness 
(Porter and Felder, 2001). Cannabis intoxication causes mood elevating and stress alleviating properties 
among many users, which largely account for its high recreational use around the world. Some of the 
positive effects of cannabis are pain relief, euphoria, relaxation, heightened sensory perception, laughter, 
altered perception of time, and increased appetite (NIDA, 2003). Cannabis use can also enhance 
sociability, reduce depressed mood and increase positive affect (Denson and Earlywine, 2006; Iversen, 
2003). Furthermore, clinical studies have reported benefits of cannabis on mood disorders (Ashton et al., 
2005; Ware et al., 2005), and one case study reported antidepressant efficacy of cannabis use among 
individuals with mood disorders (Gruber et al., 1996). However, the relationship between mental health 
disorders and cannabis is complex and will be discussed more below. 
 
1.1.3 Comorbid Cannabis Abuse and Mental Health Disorders  
According to the criteria listed by the DSM-IV, a diagnosis of substance abuse is based upon 
manifestation of at least one of four symptoms: interference with major professional or personal 
obligations, continued use in the face of persistent social or interpersonal problems, substance-related 
legal problems, and/or intoxication in hazardous settings (American Psychiatric Association, 2000). High 
comorbidity between anxiety disorder and drug use is observed in the United States. Individuals with an 
anxiety disorder are 2-3 times more likely than the general populace to experience a substance use 
disorder at some time during their life (Kessler et al., 1994). The temporal sequence of onset of anxiety 
and substance abuse disorders is complex. A history of past substance abuse often predicts panic 
disorder, social phobia and agoraphobia. Meanwhile, a previous diagnosis with an anxiety disorder is 
present in 50% of those with substance abuse disorders (Goodwin and Stein, 2013). 
As is the case with comorbid mental health disorders and other substances of abuse, co-
occurrence of cannabis abuse and mental illness are well-documented. For example, a study in Ontario 
showed that individuals with a mental illness are seven times more likely to use marijuana on a weekly 
basis than are those without a mental disorder (Cheung et al., 2010). Evidence suggests that pre-existing 
mental health problems increase the likelihood of later cannabis abuse disorder (Swift et al., 2008). 
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However, the link between pre-existing mental health disorders and later cannabis abuse may be 
mediated by negative social factors. An Ontario study on high school students found that cannabis use is 
strongly promoted by unfavorable social conditions rather than school factors (Allison and Dignam, 1990). 
Similarly, a study in Germany found that young adults were at greater risk of later cannabis abuse than 
adults. In particular, youth with risk factors such as peer group pressure, low self-esteem and parental 
mental disorders or parental death before the age of 15, are most vulnerable to later marijuana addiction 
(von Sydow et al., 2002). Correspondingly, younger cannabis users between the age of 11-12 are 
characterized as having lower academic performance, poor family relations and self-esteem, and more 
arrests than non-cannabis users. Those who initiate use between ages 14-15 present an intermediate 
between younger and older groups (Flory et al., 2004). This suggests that early age of onset and pre-
existing mental health problems, with mediating social factors, together predict later cannabis abuse 
disorder. However, evidence also suggests that cannabis use can lead to the development of mood 
disorders. Cannabis use predicts the development of anxiety disorders, depression, suicidal ideation, 
certain personality disorders and interpersonal violence; this association is stronger among adolescents 
than adults (Copeland et al., 2013). In fact, daily cannabis use among adolescents is associated with 
anxiety, even once users abstain from the drug (Degenhardt et al., 2013). Thus, the comorbid relationship 
between cannabis abuse and anxiety disorder is strong, as the odds of having one strongly increases the 
odds of having the other. 
Trauma is similarly a significant predictor of problematic cannabis use (Bon-Miller, 2011; 
Kilpatrick et al., 2000; Vlahov et al., 2002). Individuals exposed to multiple types of trauma show higher 
rates of cannabis use (Bremner et al., 1996; Kilpatrick et al., 2000; Vlahov et al., 2002). The co-
occurrence of post-traumatic stress disorder (PTSD), cannabis use and disorders also shows very high 
prevalence rates (Bonn-Miller et al., 2010; Calhoun et al., 2000). Users with high PTSD scores reported 
using cannabis to improve sleep, and for coping reasons more generally, compared with those with low 
PTSD scores (Bon-Miller et al., 2014). 
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1.2 Cannabinoids & the Endocannabinoid System  
1.2.1 Cannabinoids  
The cannabis sativa plant from which marijuana is derived contains over 480 natural components, of 
which 66 have been classified as cannabinoids unique to the plant (NCPIC, 2013). Five classes of 
cannabinoid analogs have currently been classified based upon their structure, which often correlates 
with their degree of psychological effect (Pertwee, 2005; Makriyannis, Mechoulam and Piomelli, 2004). 
These classes include: classical, non-classical, ainoalkylindoles, eicosanoids and biarylpyrazole. 
Classical cannabinoids are tricyclic terpenoid derivatives and include the main psychoactive ingredient of 
cannabis: the plant-derived cannabinoid receptor type 1 (CB1R) and cannabinoid receptor type 2 (CB2R) 
agonist Δ (9)-tetrahydrocannabinol (THC), and other synthetic equivalents (Pertwee, 2008). The two main 
constituents and most researched of the cannabinoids in cannabis sativa are THC and cannabidiol 
(CBD). THC is the principle psychoactive constituent of cannabis (see Figure 3A for molecular structure). 
Meanwhile, CBD may contribute up to 40% of cannabis resin, is not psychotropic, and may inhibit some 
behavioral effects of THC, such as its’ anxiogenic effects in humans (Zuardi et al., 2006; see Figure 3B 
for molecular structure). Cannabidol, cannabinol, and cannabigerol are phytocannabinoids that also show 
affinity for CB1R and/or CB2R (Panagis et al., 2014). Because the THC:CBD ratio is so critical to the 
effects of cannabis, it is the criteria used to define cannabis chemotypes. It is also notable that the ratio of 
these compounds has changed a great deal in marijuana sold in recent years (Potter et al., 2008) with the 
THC content or potency in marijuana increasing significantly among confiscated samples over the last 30 
years (Mehmedic et al., 2010). This means that plants with a higher amount of THC may have greater 
psychological impacts and increase anxiety levels in users than did previous plants. This change in the 
ratio of THC to CBD raises concerns about current knowledge on the effects of cannabis use, as much of 
our knowledge is derived from THC and CBD studies that used doses that are dissimilar to the marijuana 
of today. 
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Non-classical cannabinoids are bicyclic and tricyclic analogs of THC, and include potent non-selective 
CB1R and CB2R agonists such as the synthetically-derived 5-(1, 1-dimethylheptyl)-2-[5-hydroxy-2-(3-
hydroxypropyl) cyclohexyl] phenol (CP55,940, see Figure 4A for molecular structure; Pertwee, 2008). The 
eicosanoid and aminoalkylindoles have completely different chemical structures from both each other and 
classical and non-classical cannabinoids. Biarylpryazoles are a class of CB1R inverse agonists which are 
used extensively as CB1R competitive antagonists. The two most well-known members of this group 
include N-(piperidin-1-yl)-5-(4-iodo-phenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbox-amide 
(AM251) and rimonabant/SR141716 [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1- piperidinyl-
1H-pyrazole-3-carboxamide (see Figure 4B for molecular structure; Padawl and Majumdar, 2007). While 
AM251 and rimonabant are both technically CB1R inverse agonists, they are both widely used as and 
referred to by cannabinoid research as cannabinoid antagonists.  Aminoalkylindoles are less lipophilic 
and interact differently with cannabinoid receptors (CBRR) differently than the classes above, with (11R)-
2-methyl-11-[(morpholin-4-yl)methyl]-3-(naphthalene-1-carbonyl)-9-oxa-1-azatricyclo[6.3.1.0⁴,¹²]dodeca-
2,4(12),5,7-tetraene (WIN 55,212-2) being the most commonly used member of this class (Mechoulam et 
al., 1995; see Figure 5A for molecular structure). The eicosanoids include the endogenous cannabinoids 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG; Devane et al., 1992; see Figure 5B for molecular 
structure).  
 
 
Figure 3. Molecular structure of the plant-derived CBR type 1 and 2 (CB1R and CB2R) agonists  
(3|A) Δ (9)-tetrahydrocannabinol (THC) and (3|B) cannabidiol (CBD; Figure 3 is adapted from  
Iversen, 2003). 
 
A. THC B. CBD 
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Plant-derived cannabinoids such as THC and their synthetic analogs activate cell-surface receptors that 
are normally engaged by AEA or 2-AG. This artificial stimulation of CBRs disrupts the function of 
endogenous cannabinoids. The overstimulation of CBRs by THC and its’ analogs evokes the marijuana 
“high” and other effects mentioned previously (Volkow, 2012).  
 
 
A. 
A. CP55,940 B. Rimonabant 
Figure 4. Molecular structure of the CBR type 1 and 2 (CB1R/2R) agonist CP55,940 (4|A) and the CB1R 
inverse agonist rimonabant (4|B). Fig. 8 was adapted from Tocris, 2014 a/b. 
 
A. AEA 
B. 2-AG 
Figure 5. Molecular structure of the endogenous cannabinoids (5|A) anandemide (AEA) and (5|B) 2-
Arachidonylglycerol (2-AG). Figure 5 was adapted from Tocris, 2014 a/b. 
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1.2.2 CBRs and the Endocannabinoid System 
The endocannabinoid system was first identified in the early 1990s when researchers began to 
characterize the activity and effects of THC (Fonseca et al., 2013; Di Marzo et al., 2004). Endogenous 
cannabinoids, which are chemicals that are produced naturally by the body and found in the brain, help 
maintain many of the same mental and physical functions that are altered by marijuana use. The 
endocannabinoid system contains two ligands, AEA and 2-AG, which signal through CB1R and CB2R. 
Numerous pharmacological effects of THC have been identified in human and rodent models. Some of 
these include alteration to cognition, memory, emotion, temperature regulation, motor behavior, pain 
sensation, appetite control, and autonomic and neuroendocrine responses. THC elicits these effects 
primarily through activation of cannabinoid receptors (CBRs). CBRs are located on the surface of certain 
nerve cells and are found in high-densities in brain regions involved in movement, coordination, thinking, 
concentration, pleasure, memory, and sensory and time perception. CBRs are part of the 
endocannabinoid system, a system that is critical to normal brain development and function. Specifically, 
THC and THC analogs activate CBR type-1 and type-2 (CB1R and CB2R). CB1Rs are found mainly in 
nerve cell terminations, the reproductive system and some glandular systems, and their stimulation 
impacts emotion regulation and anxiety-like behaviors (Scopinho et al., 2011). Meanwhile, CB2Rs are 
involved in pain regulation and are located primarily on lymphoid organs and immune cells such as 
monocytes, but are also present in smaller numbers in the brain and cardiac cells (Rodriguez de Fonseca 
et al., 2005). THC has nanomolar affinity for CB1R (Ki = 25.1 nmol/L) and CB2R (Ki = 35.2 nmol/L; 
Tambaro and Bortolato, 2012). CB1Rs are the most widely distributed G-protein coupled receptors in the 
central nervous system (CNS) and are found in high densities in numerous brain regions, which enable 
them to play a critical role in many functions (Felder and Glass, 1998). CB1Rs found in the basal ganglia 
and cerebellum impact motor movement and coordination respectively. Brain regions critical to regulation 
of emotional responsiveness and perception and memory also hold a high density of CB1Rs. These 
include the prefrontal cortex, amygdala, striatum, nucleus accumbens and hippocampus (Filbey et al., 
2010; Gruber et al., 2009). CB1Rs in the hypothalamus impact the autonomic nervous system and basic 
functions such as temperature regulation, hunger, thirst, and sleep. And finally, the high density of CB1Rs 
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in the hippocampus influence memory while those in the central gray substance impact analgesia (Figure 
6, NIDA 2011; Gonzalez et al., 2005). 
 
CB1Rs are primarily located on axons and nerve terminals and are nearly absent from neuronal dendrites 
or soma. The primarily pre- rather than post-synaptic location of CB1Rs is consistent with an interaction 
with many neurotransmitters and neuromodulators in both the central and peripheral nervous systems 
(Iversen, 2003). The presynaptic CB1Rs are believed to be critical to neurotransmitter release and 
synaptic plasticity (Figure 7, Guzman 2003; Tambaro and Bortolato, 2012). 
Figure 6. Locations and Effects of CBRs in the Brain (Figure 6 was adapted from NIDA, 2011). 
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Figure 7. The endogenous cannabinoid system. The endogenous cannabinoid system plays a critical role 
in brain neuromodulation. An increase of cytosolic free Ca2+ concentrations causes postsynaptic neurons 
to synthesize endocannabinoid precursors and cleave them to release active endocannabinoids. This 
could occur following binding of neurotransmitters to their ionotropic (iR) or metabotropic (mR) receptors 
for example. Endocannabinoids thus act as retrograde messengers by binding to presynaptic CB1R that 
inhibit voltage-sensitive Ca2+ channels and activate K+ channels. This membrane depolarization inhibits 
the release of NTs such as glutamate, dopamine and -aminobutyric acid (GABA). Effecting these 
diverse neurotransmitters impacts numerous processes such as learning, movement and memory. An as-
yet unidentified membrane transport system (T) terminates endocannabinoid neuromodulatory signaling. 
Next, a family of intracellular degradative enzymes, the best characterized of which is fatty acid amide 
hydrolase (FAAH), degrades AEA to its component chemicals, arachidonic acid and ethanolamine (Figure 
7 was adapted from Guzman, 2003). 
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The presynaptic CBRs lie on neurons that release both excitatory and inhibitory neurotransmitters. CB1R 
activation can therefore be inhibitory or excitatory. In inhibition, an excitatory neurotransmitter is inhibited: 
there is a depolarization-induced suppression of excitation (Wilson and Nicoll, 2001). Conversely, during 
excitation, an inhibitory neurotransmitter is inhibited via depolarization-induced suppression of inhibition 
(Wilson and Nicoll, 2001). CB1Rs are coupled with Gi or Go protein, positively to mitogen-activated 
protein kinase (MAPK) and negatively to adenylyl cyclase (AC; Howlett, 1984; Howlett and Fleming, 
1984). This process attenuates cyclic adenosine monophosphate (cAMP) production, which leads to the 
inhibition of cAMP-dependent protein kinase A (PKA) activity. The decrease in PKA activity causes a 
corresponding reduction in gene expression through decreasing cAMP response element (CRE) activity, 
and activation of extracellular signal-regulated kinase (ERK; Bosier, 2010). Normally in the absence of 
cannabinoids, PKA will phosphorylate the potassium channel protein, which lowers the outward 
potassium current (Egertová et al., 1998). Thus, the CB1R positively regulates inwardly rectifying 
potassium channels while it negatively regulates voltage-gated calcium channels (Bosier, 2010). In this 
manner, CB1R-expressing presynaptic terminals likely reduce neurotransmitter release via inhibition of 
presynaptic calcium channels (Figure 8, Marzo et al., 2005; Svíženská, 2008).   
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It is via these mechanisms that cannabinoids are involved in the regulation of neurotransmitter 
release. Additionally, the synthesis of endocannabinoids is on a stimulus-dependent basis in postsynaptic 
neurons, which when triggered immediately diffuses to the synaptic cleft (Wilson and Nicoll, 2001). In 
sum, endocannabinoids are often “on demand” retrograde messengers that inhibit neural activity. For 
example, CB1R activation causes retrograde inhibition of neuronal release of a number of compounds: 
acetylcholine, dopamine (DA), γ-aminobutyric acid (GABA), histamine, serotonin (5-HT), glutamate 
(GLU), cholecystokinin, D- aspartate, glycine, and noradrenaline (Grotenhermen and Müller-Vahl, 2012). 
Furthermore, CB1R receptors are key to regulation of neurochemical substrates implicated in anxiety 
such as norepinephrine and acetylcholine, and stress-related substances such as colecystokynin, opioid 
peptides, p38 and c-jun amino terminal kinase (Tambaro and Bortolato, 2012; Liu et al., 2000). Thus, 
Figure 8. Major signaling pathways associated with CBR activation by agonists. CB1R and CB2R 
receptor activation leads to stimulation of Gi/o proteins, which is coupled to inhibition of adenylyl cyclase 
(AC) with corresponding inactivation of the protein kinase A (PKA) phosphorylation pathway, or to 
stimulation of mitogen-activated protein kinase (MAPK). This intracellular activity leads to the regulation of 
expression of several genes, among other effects (Figure 8 was adapted from Marzo et al., 2004). 
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neural inhibition allows CB1R receptors to have important effects on brain regions which modulate a 
multitude of behaviors. 
 The endocannabinoid system interacts with other signal transduction pathways. When activated 
individually, the D2 and CB1 receptors couple and together inhibit AC to decrease cellular cAMP levels. If 
both receptors are activated simultaneously however, this creates an increase in cellular cAMP levels 
(Glass and Felder, 1997). DA agonists activating D2 receptors can also increase release of the 
endogenous cannabinoid ligand AEA (Giuffrida et al., 1999). Additionally, different agonists occupying the 
CBR can impact coupling of CBRs to specific types of G-proteins (Glass and Northrup, 1999).  
 Endocannabinoid signaling terminates in a two-step manner which includes transport into cells 
and hydrolysis by two enzymatic systems (Rodriguez de Fonseca et al., 2005; Figure 7). AEA transport is 
rapid, saturable, temperature dependent, is not coupled to ion gradients, and does not need ATP (Hillard 
et al., 1997; Di Marzo et al., 1994).  The AEA transporter likely takes other ligands in addition to AEA and 
THC (Rakhshan et al., 2000). The AEA transport protein is as yet still unidentified. Two metabolizing 
enzymes are critical to endocannabinoid deactivation. These are fatty acid amide hydrolase (FAAH), 
which is the main hydrolase for AEA, while 2-AG is inactivated by two enzymes called monoacyl-gyceral 
lipases (MAGLs; Castillo et al., 2012). 
 
1.2.3 The Endocannabinoid System and Neurogenesis  
CBRs play a critical role in the developing brain (Fernandez-Ruiz et al., 2000).  CBR binding occurs in the 
developing human (Mailleux and Vanderhaeghen, 1992) and rat (Rodriguez de Fonseca et al., 1993) 
brain. Fetal and neonatal human brains have substantially higher CB1R expression compared to adult 
brains. Certain neonatal brain regions also express high levels of CBRs, which later show low levels 
during adulthood (Glass et al., 1997). In rats, CB1R mRNA (messenger ribonucleic acid) is seen at 
embryonic day 11 in the neural tube, while CB2R mRNA is evident at embryonic day 13, demonstrating 
CBR receptor development during very early development (Buckley et al., 1998). Interestingly however, 
CB1R, CB2R and CB1R/CB2R knockout mice show no developmental defects, only a higher mortality 
rate in CB1R-knockout (KO) mice with an as yet unknown cause (Buckely et al., 2000; Zimmer et al., 
1999; Jarai et al., 1999).  
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Endocannabinoids are prevalent throughout most of the brain, and modulate plasticity and adult 
neurogenesis. Constituents of the endocannabinoid system that are implicated in adult neurogenesis 
include the endogenous cannabinoids AEA and 2-AG, the AEA-degrading enzyme FAAH and the 2-AG 
synthesizing enzyme diacylglycerol lipases (Harkany et al., 2007; Aguado et al., 2005; Goncalves et al., 
2008). For instance, neural progenitor differentiation in the adult brain is controlled by endocannabinoid 
signaling via promoting astroglial differentiation of new-born cells (Aguado et al., 2006). Furthermore, 
AEA inhibited neuronal progenitor cell differentiation while the AEA analogue methAEA decreased and 
the CB1R antagonist rimonabant increased adult neurogenesis in the dentate gyrus (Rueda, Navarro, 
Martinez-Serrano, Guzman and Galve-Roperh, 2002). Results are also mixed showing both increased 
and decreased adult neurogenesis following stimulation of CB1R receptors or exposure to the CBR 
agonist HU210 (Aguado et al., 2005; Aguado et al., 2002). Evidence also suggests that CBD does not 
impair learning and actually increases adult neurogenesis, while THC reduces learning without affecting 
neurogenesis by impacting proliferative progenitor cells and the survival and maturation of new neurons 
(Wolf et al., 2010).   
The endocannabinoid system is also implicated in neural plasticity via its effect on the immediate 
early gene cFOS. CFOS is an mRNA and protein that is rapidly and transiently induced within about 
fifteen minutes of stimulation, and is thus one of the first proteins expressed, before any new proteins are 
synthesized (Hu et al., 1994). Posttranslational modification caused by phosphorylation by different 
kinases such as PKA and MAPK regulates cFOS activity. These kinases impact protein stability, DNA-
binding and trans-activation of transcription factors (Hurd et al., 2002; Rosenberger et al., 1999). CFOS is 
involved in numerous cellular events, including cell proliferation, differentiation, survival, and gene 
activation or suppression (Tuchinsky, 2000). Acute THC (5 mg/kg i.p.) increases cFOS expression in the 
hypothalamus, lateral septum and amygdala (McGregor et al., 1998). Chronic THC treatment (15 mg/kg 
i.p. for 6.5 days) similarly caused an increase in cFOS levels in the prefrontal cortex and cerebellum 
(Rubino et al., 2004). Meanwhile, a low acute dose of THC (0.75 mg/kg) significantly reduced cFOS in the 
prefrontal cortex and hippocampus (Rubino et al., 2007).  
The endocannabinoid system modulates the firing of DA neurons, and is key to inducing certain 
DA-dependent forms of synaptic plasticity (Melis and Pistis, 2007; Kauer and Malenka, 2007). For 
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example, one critical part of learning is long-term depression (LTD). LTD is an activity-dependent 
reduction in the efficacy of neuronal synapses lasting hours or longer following a long patterned stimulus 
(Purves et al., 2001). Drugs of abuse such as cocaine can reduce the efficacy of this process (Kauer and 
Malenka, 2007). Furthermore, the endocannabinoid system mediates the process of LTD.  As discussed 
previously, CBRs function as presynaptic inhibitors in much of the brain, which can impact LTD at 
corticostriatal and glutamatergic synapses of the nucleus accumbens (Thomas et al., 2000). In the 
basolateral amygdala and hippocampus, endocannabinoids are also involved in LTD of inhibitory inputs 
(Gerdeman and Lovinger, 2003). The induction of LTD in the striatum demonstrates the complex 
interaction between the endocannabinoid and dopaminergic systems, in addition to their interactions with 
other neurotransmitter system (Mathur and Lovinger, 2012, Figure 9). 
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Figure 9. Interactions between endocannabinoid and dopaminergic systems in striatal long-term 
depression (LTD). Four, one second bouts of afferent (corticostriatal, CTX) stimulation at 100 Hz (high 
frequency stimulation, HFS) synchronized with postsynaptic medium spiny neuron (MSN) depolarization 
(depol.) to 0 mV every ten seconds induces endocannabinoid (ECBR)-mediated LTD (ECBR-LTD). To 
induce ECBR-LTD, metabotropic glutamate receptor (mGluR) are activated, as is dopamine (DA) D2 
receptor activation on tonically active cholinergic interneurons (TANs) which causes suppression of 
cholinergic tone. When cholinergic tone on M1 acetylcholine (ACh) receptors is relieved and coupled with 
postsynaptic depolarization, this enhances activation of L-type voltage-gated calcium channels (VGCCs), 
which causes an influx of calcium (Ca2+). This triggers ECBR production and thus frees eCBRs that send 
a retrograde signal to activate presynaptic cannabinoid type 1 receptors (CB1R). This results in persistent 
suppression of glutamate release. Adenosine A2A receptors are also the location of action on both TANs 
and D2 receptor expressing (indirect pathway) MSNs. A balance between A2A and D2 receptor activation 
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may oversee downstream effectors modulating eCBR production, including PKA/cAMP and RGS4. These 
then control mGluR5-induced signaling. Serotonin (5-HT) also has a role in modulation of substantia nigra 
DA cell firing and excitation of TANs. Furthermore, LTD is induced by serotonergic activation of 
corticostriatal 5-HT1b receptors that is mutually occlusive with ECBR-LTD. Thus, a complex interaction 
exists between several neurotransmitter systems which impact the corticostriatal synapse (Figure 9 was 
adapted from Mathur and Lovinger, 2012).  
 
1.2.4 The Endocannabinoid System and Addiction 
DA neurons of the ventral tegmental area (VTA) and the substantia nigra (SNc) are key factors in 
reward function and addiction. These neurons terminate in the striatum, amygdala, hippocampus and 
prefrontal cortex which are implicated in reward-related behaviors (Fattore et al., 2010a). These include 
reinforcement and habit formation (striatum), learning and memory (hippocampus), emotional memory 
(amygdala) and executive functions and working memory (prefrontal cortex; Wise 2009). The VTA and 
SNc contain CB1Rs located on GABAergic and glutamatergic terminals where CB1Rs fine-tune the 
release of GABA and GLU and thereby regulate DA neuron firing (Marinelli et al., 2007; Melis et al., 
2004). Endocannabinoid release by DA neurons can be evoked by stimuli that cause burst firing of DA 
neurons, which involves phasic elevation of synaptic DA levels (Melis et al., 2004). The burst firing of DA 
neurons correlates with rewarding activity (Valentin and O’Doherty, 2009; Succu et al., 2007). DA 
neurons also possess the enzymatic machinery needed to create 2-AG (Matyas et al., 2008) which is 
released as a retrograde messenger and modulates inputs by acting at CB1Rs (Riegel and Lupica 2004). 
In sum, the role of endocannabinoids in DA burst activity may be critical to reward learning and thus 
addiction.  
The endocannabinoid system is able to modulate the activity of DA neurons through regulating 
the phosphorylation of DARPP-32 (dopamine- and adenosine 3',5'-monophosphate-regulated 
phosphoprotein of Mr = 32,000; also called dopamine- and cAMP-regulated neuronal phosphoprotein. 
DARPP-32 is a mechanism for integration of information that arrives at dopaminoceptive neurons in 
numerous brain regions via neuromodulators, neuropeptides, neurotransmitters and steroid hormones. It 
is also a major target for DA and PKA in striatum. Muscarinic and/or glutamatergic agonists applied to 
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neurons evokes Ca2+ waves propagating from the dendritic tree into the nucleus, which may in turn 
activate DARPP-32-mediated gene transcription and phosphorylation of target proteins (Power and Sah, 
2007). DARPP-32 phosphorylation at Thr34 activates PKA or PKG and thereby converts DARPP-32 into 
a potent inhibitor of protein phosphatase-1 (PP-1; Hemmings et al., 1984). This in turn, prevents 
dephosphorylation of downstream target proteins, thereby amplifying the effects produced by activation of 
the cAMP/PKA cascade (Greengard, 2001; Price and Mumby, 1999; Fienberg et al., 1998). DARPP-32 is 
also phosphorylated at Thr75 by cyclin-dependent kinase 5 (cdk5) and this converts DARPP-32 into an 
inhibitor of PKA. D2 receptors are coexpressed with adenosine A2A receptors in a large population of 
striatal medium spiny neurons. In these cells, the state of phosphorylation of DARPP-32 at Thr34 reflects 
a balance between activation of adenosine A2A receptors, which stimulate PKA by increasing the 
production of cAMP, and activation of D2 receptors, which reduce PKA activity via inhibition of the 
production of cAMP. Thus, increases in Thr34 phosphorylation produced by blockade of D2 receptors are 
dependent on intact adenosine A2A receptor transmission (Svenningsson et al., 2000).  
DARPP-32 therefore has the unique property of being a dual-function protein, acting either as an 
inhibitor of PP-1 or of PKA. Phosphorylation of DARPP-32 at Thr34 is dependent upon on the 
phosphorylation state of two serine residues, Ser102 and Ser137. These serine residues are 
phosphorylated by CK2 and CK1, respectively. DARPP-32 participates in several neural functions, such 
as LTP, long-term depression (LDP), and memory formation (Mansuy, 2003). Because DARPP-32 can 
modulate the activity of PP-1 and PKA, it is critically involved in regulating electrophysiological, 
transcriptional, and behavioral responses to physiological and pharmacological stimuli, including 
antidepressants, neuroleptics, and drugs of abuse (Svenningsson et al., 2004). Abnormal physiological 
conditions, such as psychostimulant stimulation would have significant impact on either expression or 
functions of DARPP-32 (Lin et al., 2002; Centonze et al., 2004; Rushlow et al., 2005). DARPP-32 is 
implicated in the generation of motor responses produced by various classes of drugs that activate or 
inhibit the cAMP/PKA pathway in striatal medium spiny neurons. Thus, changes in DARPP-32 
phosphorylation are involved in the psychomotor effects produced by amphetamine (Fienberg et al., 
1998), caffeine (Lindskog et al., 2002), and anti-psychotics (Fienberg et al., 1998). 
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DARPP-32 is highly expressed in several forebrain dopaminergic terminals, where it acts as a 
modulator of the cAMP pathway. DARPP-32 is highly expressed in the medium spiny neurons of the 
striatum (Ouimet et al., 1998; Walaas and Greengard, 1984). CB1R activation of those neurons induces 
the phosphorylation of DARPP-32 through PKA, while inactivation of the PKA phosphorylation site on 
DARP-32 impairs the psychomotor effects of CB1R agonists (Andersson et al., 2005). CB1Rs form 
heterodimers with A2A receptors (Carriba et al., 2007) and D2 receptors (Glass and Felder, 1997; 
Jarrahian et al., 2004; Kearn et al., 2004). A precondition to the motor effects of cannabinoids is intact 
signaling at A2A receptors (Carriba et al., 2007). If D2 and A2A receptor signaling is disrupted, the ability 
of CB1Rs to cause motor depressant effects through the phosphorylation of DARPP-32 is impaired. 
DARP-32 is a critical integrator of molecular signaling at the nuclear level as it is at the crossroads of 
calcium-dependent PKA and protein kinase C phosporylation (Chen et al., 2007). For example, male 
Sprague-Dawley rats given chronic methamphetamine showed a progressive decrease in numbers of the 
CB1Rs. Microinjection of CB1R antagonist SR147778 into the nucleus accumbens significantly 
suppressed behavioral sensitization to methamphetamine. In nucleus accumbens brain slice preparation, 
acute incubation with CB1R agonist CP55,940 dose-dependently enhanced cAMP accumulation and 
down-stream DA and DARPP-32Thr34 levels in sensitized rats. (Chiang and Chen, 2007). 
DARPP-32 is involved in the generation of motor responses produced by psychostimulants that 
modulate the cAMP/PKA pathway (Ferre, 1997; Lindskog et al., 2002; Svenningsson et al., 2002). 
Cannabinoids evoke their motor suppressant effects via a signaling cascade in striatal projection neurons 
involving PKA-dependent phosphorylation of DARPP-32 which is achieved through modulating D2 and 
adenosine A2A transmission (Borgkvist and Fisone, 2007).  Andersson et al. 2005 provided ample 
evidence of an interaction between DARPP-32, CB1Rs and motor behavior. Administration of the CBR 
agonists CP55,940 and WIN-55,212-2, causes an increase in DARPP-32. Accordingly, genetic 
inactivation of DARPP-32 or a point mutation of Thr34 (the PKA phosphorylation site of DARPP-32), both 
attenuate the motor depressant effects of CP55,940. Activation of CB1Rs via agonist or inhibition of 
reuptake of endogenous cannabinoids, stimulated phosphorylation at Thr34. This converted DARPP-32 
into an inhibitor of PP1 (Andersson et al., 2005). Lastly, the genetic inactivation of D2 receptors or of 
adenosine A2A receptors reduced phosphorylation of DARPP-32 at Thr34 and with it the motor 
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depression caused by CP55,940 (Andersson, 2005). A study using THC found similar motor effects that 
were mediated by DARPP-32. THC increased DARPP-32 phosphorylation at Thr34 both in dorsal 
striatum and nucleus accumbens, which was reduced by the CB1R antagonist rimonabant. The D1 
receptor antagonist SCH23390, or the adenosine A2A receptor antagonist KW6002A similarly attenuated 
the effect of THC. These results collectively indicate that cannabinoids promote PKA-dependent 
phosphorylation of DARPP-32 in striatal medium spiny neurons expressing D1 and adenosine A2A 
receptors (Borgkvist et al., 2008). Polissidis 2010 showed that high and low doses of THC increased 
DARPP-32 phosphorylation in the striatum, nucleus accumbens, prefrontal cortex and amygdala. 
DARPP-32 phosphorylation was also significantly higher in the striatum of rats treated with a high-dose of 
WIN55,212-2. Interestingly, DA levels were increased in the brains of rats that responded highly to novel 
environments, but not in those that responded poorly to novel environments (based on vertical activity; 
Polissidis 2010).  
Addiction is influenced by the endocannabinoid system also via its’ impact on the ERK pathway. 
Cyclic AMP-responsive-element-binding protein (CREB) is a transcription factor and downstream target of 
the ERK pathway (Lonze and Ginty, 2002). The phosphorylation state of CREB is ERK-dependent in the 
learning, memory, and formation of long-term potentiation (LTP). When ERK activation is depressed, the 
CREB phosphorylation is impaired (Ying et al., 2002; Hardingham). CREB is a cellular transcription factor. 
It binds to certain DNA sequences and thereby controls the rate of transcription of genetic information 
from DNA to mRNA (Bourtchuladze et al., 1994). In particular, it binds to CRE, and in doing so, increases 
or decreases the transcription of the downstream genes. The transcription of numerous genes, such as 
cFOS, BDNF, tyrosine hydroxylase and many neuropeptides are regulated by CREB (Purves et al., 
2008). CREB has been implicated in neuronal plasticity, long-term memory, spatial memory and affect 
(Silva, 1998). On the other hand, numerous protein kinases regulate CREB activity differently, for 
instance, PKA phosphorylates CREB and leads to activation of gene transcription (Carlezon, Duman and 
Nestler, 2005).   
Drugs of addiction cause changes in the phosphorylation and activity of CREB in the prefrontal 
cortex and hippocampus in adult rodents (McDaid, Graham and Napier, 2006; Edwards et al., 2007). 
Cocaine for example, causes a DA-dependent phosphorylation of ERK, a signaling molecule of the MAPK 
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signal transduction family (Jenab et al., 2005; Sun et al., 2008). Alcohol similarly causes changes in 
CREB activity. Alcohol-preferring rats had lower CREB and phosphorylated CREB in central and medial 
amygdala, but not basolateral amygdala compared to non-preferring rats (Pandey et al., 2005). Lastly, 
cannabinoids have biphasic and sex-specific effects on CREB activity. THC microinjected at low doses 
increased CREB activity while high doses did the reverse in the amygdala (Rubino et al., 2008a). Rats 
treated with 0.075 to 1.5 mg/kg THC showed a significant increase in CREB activation in the prefrontal 
cortex and hippocampus. In the prefrontal cortex this increased activation was linked to an increase in 
ERK activation, whereas in the hippocampus there was a drop in the activity of calcium/calmodulin-
dependent protein kinase II (CAMKII), a kinase with inhibitory effect on CREB activation. All these effects 
were reversed by AM251 pretreatment, suggesting that stimulation of CB1Rs is fundamental for triggering 
the biochemical events (Rubino et al., 2007). Adolescent rodents exposed to chronic THC showed a sex-
difference in CREB changes, with only females showing low CREB activity in the hippocampus and 
prefrontal cortex and high CREB levels in the nucleus accumbens (Rubino et al., 2008b).  
  
1.2.5 The Endocannabinoid System and Anxiety 
The endocannabinoid system is involved in anxiety via its interaction with the hypothalamic pituitary-
adrenal (HPA) axis. The HPA axis activates following exposure to a stressful stimulus. Multiple sensory 
and limbic brain system signals are activated by stress and their information integrated in the 
paraventricular nucleus (PVN) of the hypothalamus (Patel et al., 2004). Neurons in the PVN release 
corticotropin-releasing hormone into the anterior pituitary (Senst and Bains, 2014). The anterior pituitary 
then releases adrenocorticotropic hormone into the general circulation, which stimulates the adrenal 
cortex to produce glucocorticoid hormones, the most notable of these being corticosterone (Fig 10A, 
Senst and Bains, 2014). Certain other glucocorticoids are part of a negative feedback of HPA initiation to 
curtail activation (Figure 10B, Senst and Bains, 2014). High corticosterone levels impair this 
glucocorticoid-mediated negative feedback regulation of the HPA axis (Patel et al., 2004). Thus, the HPA 
axis redirects energy stores for a rapid stress response, which is beneficial to survival in the short term, 
but if activated long-term, can have a negative impact on mood, cognition, and metabolism, and is 
associated with anxiety and mood disorders (Wolkowitz et al., 2001). 
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Figure 10. Summary of the hypothalamic–pituitary–adrenal (HPA) axis stress response. (A) Information 
from limbic brain regions impacted by stress converge on parvocellular neuroendocrine cells (PNCs) in 
the paraventricular nucleus of the hypothalamus (PVN). Corticotropin-releasing hormone (CRH) is 
produced by PNCs and released at the anterior pituitary. Adrenocorticotropic hormone (ACTH) is then 
produced and released into the general circulation, stimulating the adrenal cortex to produce 
glucocorticoid hormones which have numerous systemic effects. (B) Glucocorticoids (GCs) are part of a 
negative feedback loop (green lines) at multiple levels of HPA initiation to curtail activation. BNST, bed 
nucleus of the stria terminalis; DMH, dorsomedial hypothalamic nucleus; NTS, nucleus tractus solitaries 
(Figure 10 was adapted from Senst, 2014). 
 
The endocannabinoid system is an important regulator of the stress response, via the 
endogenous cannabinoids 2-AG and AEA. These endocannabinoids are synthesized and/or released in 
response to altered neural activity, rather than being stored or released in the vesicles (Sugiura et al., 
2002). The synthesis of 2-AG or AEA happens on separate enzymatic cascades and are evoked by 
neuronal depolarization, intracellular calcium elevations, and activation of metabotropic and excitatory 
ionotropic neurotransmitter receptors (Freund et al., 2003; Sugiura et al., 2002). Increased 
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endocannabinoid activity suppresses glucocorticoid release, while chronic stress and HPA activity can 
cause long-term changes to the endocannabinoid system (Gorzalka and Hill, 2009). The 
endocannabinoid system acts as a negative feedback loop to prevent maladaptive, excess activation of 
the HPA axis, and AEA is key to this relationship, as low AEA levels are a pre-requisite to the occurrence 
of the HPA stress response (Figure 11, Tasker, 2004; Gorzalka and Hill, 2009). 
 
Figure 11. Endocannabinoid suppression of stress-induced activation of the HPA axis (Figure 11 was 
adapted from Tasker 2004). 
CFOS expression is the most commonly used functional anatomical mapping tool used to identify 
cells and extended circuitries that are activated in response to various stimuli, including those that alter 
anxiety (Kovacs, 1998). CFOS or its protein product FOS regulate differential patterns of activation for 
different classes of stressors (Briski and Gillen, 2001; Dayas et al., 2001). For example, physical 
stressors are things like pain and infection, while psychological stressors include variables such as 
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restraint or novel environment (Emmert and Herman, 1999). Numerous studies document that stress 
results in an increase in cFOS levels in certain areas of the brain. Ironically, the elevated plus maze 
(EPM) and open field (OF) paradigms, which are paradigms used to assess anxiety levels, are stressors 
themselves. Rats showing higher anxiety levels on the EPM and OF showed increases in p-ERK and 
cFOS during their anxious state, and inhibition of ERK phosphorylation blocked the anxiety-induced cFOS 
expression (Ailing et al., 2009). In another study, early maternal separation (EMS) caused an increase in 
cFOS mRNA expression in cingulate cortex, medial amygdala and hippocampus, along with increased 
anxiety-like behavior on the EPM rats compared to controls. Meanwhile, an increase in cFOS levels in the 
dentate gyrus and piriform cortex were only seen when animals were exposed to both EMS and EPM. 
Controls who received only one or neither condition showed no change in cFOS levels to the two 
aforementioned brain regions (Troakes and Ingram, 2009). In another study, rats were exposed to 
predator or submersion stress followed by the EPM and hole board test. Predator stress elevated cFOS 
levels in the mPFC and medial amygdala, while submersion stress had no impact on cFOS levels. 
(Adamec et al., 2012). Accordingly, animals treated with low-acute anxiolytic doses (0.015 to 0.075 
mg/kg) of THC show an increase in time spent in the open arms of the EPM, with significantly lower cFOS 
levels in the prefrontal cortex and amygdala. This can be reversed by AM251, which suggests a role of 
CB1Rs in the dynamic between anxiety and cFOS levels (Rubino et al., 2007).  
The ERK signal pathway is also implicated in anxiety and depression, and also interacts with the 
endocannabinoid system. The pathway is disrupted in depressed animals; this disruption is reversed after 
ERK inhibition or systematic administration of antidepressants (Qi et al., 2008; Todorovic et al., 2008; 
Tronson et al., 2008; Qi et al., 2006). Phosphorylated CREB is likely integral to regulating anxiety-like 
behavior in rats (Barrot et al., 2002; Pandy et al., 2005). Disruption of CREB function in the nucleus 
accumbens or sustained reductions in its activation lead to an increase in anxiety (Barrot et al., 2002; 
Barrot et al., 2005) and decreased CREB phosphorylation in the amygdala may be responsible for 
predisposition to anxiety (Pandey et al., 2005). Sub-chronic ERK inhibition to the dorsal hippocampus and 
medial prefrontal cortex causes depressive-like behavior on the EPM (increased closed-arm time), open 
field test (reduced rearing and distance traveled) and saccharin test (reduced intake; Qi et al., 2009). 
Sub-chronic ERK inhibition to the dHP and mPFC causes a reduction in the p-CREB (Qi et al., 2009).   
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Cannabinoids impact anxiety-like behavior in rodents in part through influencing levels of ERK 
and CREB. In vivo stimulation of CB1Rs effects PKA and ERK activity (Rubino et al., 2004; Rubino et al., 
2000; Valjent et al., 2001). Rubino et al. found that acute or chronic THC caused a significant increase in 
ERK, cAMP and PKA levels in the caudate-putamen, cerebellum, stratum and cortex (2004 and 2000). 
Low doses of THC cause an increase in open-arm time in the EPM, thus an anxiolytic effect, which is 
accompanied by an increase in CREB levels in the prefrontal cortex and hippocampus (Rubino et al., 
2007). Low-dose THC microinjection to the prefrontal cortex and hippocampus caused an anxiolytic-like 
response on the EPM, while higher doses were anxiogenic. Low THC doses in the basolateral amygdala 
produced an anxiogenic-like response whereas higher doses were ineffective. THC anxiolytic activity in 
the prefrontal cortex and ventral hippocampus was paralleled by an increase in CREB activation, whilst 
THC anxiogenic response in the basolateral amygdala was paralleled by a decrease in CREB activation. 
This suggested that mild activation of CB1Rs in the prefrontal cortex and ventral hippocampus attenuate 
anxiety, while a slight CB1R stimulation in the amygdala results in an anxiogenic-like response (Rubino et 
al., 2008a). 
CREB also regulates molecules that are critical to the expression of anxiety, such as BDNF and 
neuropeptide Y. The neurotrophin BDNF has been implicated in a variety of affective disorders including 
anxiety and depression (Bergami et al., 2009; Martinowich et al., 2007). Multiple classes of 
antidepressant drugs significantly increase BDNF mRNA expression in the hippocampus and prefrontal 
cortex which are brain regions implicated in anxiety and depression (Duman and Monteggia, 2006). This 
neurotrophin is thought to enhance neurogenesis (Li et al., 2001) via its receptor, tyrosine kinase B 
(TrkB), which activates a variety of downstream signaling pathways including ERKs (Patapoutian and 
Reichardt, 2001). BDNF binding to TrkB activates several signaling pathways (Kaplan and Miller, 2000), 
which subsequently induce biological responses including protection against stress-induced neuronal 
damage. The expression of BDNF is partially regulated by the transcription factor CREB (Conti et al., 
2002), which represents a central integrator of signaling from a number of extracellular stimuli that 
influence neuronal plasticity and survival (Duman, 2002). Most neuronal effects of BDNF are mediated 
through the high-affinity tyrosine kinase receptor (TrkB). Neuropeptide Y (NPY) is one of several CREB-
related target genes (Pandey et al., 2004; McClung and Nestler, 2003) and has been shown to play a role 
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in anxiety and drug abuse (Pandey, 2003; Heilig, 2004). NPY-null mutant mice also display more anxiety-
like behaviors and consume high amounts of alcohol (Palmiter et al., 1998). Predator stress causes 
increases in p-CREB expression in the amygdala, dorsal periaqueductal gray and supramammillary 
nucleus at different time points after exposure. This suggests alteration of neuroplasticity in said brain 
regions in formation of sensitized responses to fear provoking stimuli and memory (Adamec et al., 2011; 
Silva et al., 1998). 
1.2.6 Transgenic Research: CB1R Knockout Mice  
Transgenic mice lacking CB1R, CB2R, or both receptors, and those deficient in FAAH and/or MAGL have 
been used in recent research to elucidate the pharmacological and behavioral activity of cannabinoids 
(Maldanado et al., 2013; Valverde et al., 2005; Cravatt et al., 2001; Kunos and Batkai, 2001). CBR type-1 
knockout (CB1R-KO) mice have a targeted mutation in the CB1R gene.  Transgenic mice lacking the 
CB1R show increases in anxiety and depression-like behaviors. For example, these animals exhibit more 
passive stress coping behaviors in the forced swim test and tail suspension tests, show greater 
anhedonic effects of chronic stress, and changes in reward salience, all of which represent a depressive-
like phenotype (Steiner et al., 2008; Aso et al., 2008; Martin et al., 2002; Hill and Gorzalka, 2005). CB1R-
KO mice also show increases in anxiogenic-like traits when in the elevated plus-maze (EPM), light-dark 
test and social interaction test, and greater increases in CORT following restraint (Haller et al., 2002; 
Maccarrone et al., 2002; Martin et al., 2002; Urigüen et al., 2004). 
 
1.2.7 The Endocannabinoid System and the Neuroendocrine System 
The endocannabinoid system is also critical to a healthy neuroendocrine system, and evidence suggests 
extensive interaction between the two. Elements of the endocannabinoid system are present throughout 
the hypothalamic-pituitary-gonadal (HPG) axis, and alterations in the endocannabinoid system within the 
HPG alter the HPG. Accordingly, alteration of the HPG axis can change expression and function of 
endocannabinoid proteins. Lastly, many behavioral and physiological functions that are regulated by 
gonadal hormones, such as sexual behavior, are impacted by the endocannabinoid system (Gorzalka 
and Dang, 2012).  
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The endocannabinoid system is linked to male sexual function and androgens. The effects of 
cannabinoids on sexual activity may be dose-dependent, with low doses increasing sexual desire and 
pleasure, while high doses decrease sexual potency (Gorzalka and Dang, 2012). Human males may 
experience higher rates of erectile dysfunction with chronic THC use (Aversa et al., 2008; Halikas et al., 
1982), despite reporting increased pleasure and duration (Halikas et al., 1978). Acute THC in male rats 
reduced sexual approaches to females, mount latency and ejaculation latency, while increasing length of 
the refractory period after ejaculation in male rats (Navarro et al., 1993; Merari et al., 1973). On the other 
hand, the CB1R antagonist AM-251 facilitated sexual functioning (Gorzalka et al., 2008).   
Animal models have shown reductions in testosterone (Jakubovic et al., 1979), testicular 
degeneration (Dixit et al., 1977) and elimination of spermatogenesis following exposure to THC (Dixit et 
al., 1974). CB1Rs are important to the development of Leydig cells (the cells which produce testosterone) 
during postnatal development, and are also expressed in adult Leydig cells (Cacciola et al., 2008; Gye et 
al., 2005). Meanwhile, high concentrations of AEA are found inside the testes (Suguira et al., 1996). 
Furthermore, sperm-producing Sertoli cells contain CB2R, 2-AG and FAAH, suggestive of direct 
involvement of endocannabinoids in modulation of androgen-mediated spermatogenesis (Battista et al., 
2008; Maccarrone et al., 2002). THC, cannabidiol, cannabinol and AEA all lower not only circulating 
testosterone, but also luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in male rats 
(Wenger et al., 2001; Murphy et al., 1990). In males, LH stimulates Leydig cells to produce testosterone 
and FSH stimulates Sertoli cells to begin spermatogenesis. Furthermore, acute THC dose-dependently 
decreased gonadotropin-releasing hormone (GnRH, a hormone that releases FSH and LH) while GnRH 
suppression increased AEA synthesis in the hypothalamus of rats (Kumar and Chen, 1983; Fernandez-
Solari et al., 2006). This is consistent with other results indicating that the hypothalamus has dense CB1R 
localization and endocannabinoid signaling (Gammon et al., 2005).  Lastly, castration of male rats causes 
a reduction in CB1R density in the parotid gland, which is reversed by testosterone administration (Busch, 
et al., 2006). Castration also reduces CB1R mRNA transcription in the anterior pituitary of rats (Battista et 
al., 2008). The down-regulation of CB1R expression from chronic THC does not occur in castrated males, 
suggesting that androgens mediate the THC down-regulation of CB1Rs in the anterior pituitary. These 
28 
 
 
studies suggest a negative feedback loop between the endocannabinoid system and gonadal androgen 
release.    
The endocannabinoid system and estrogens interact substantially. CB1Rs and CB2Rs, FAAH, 
and the AEA synthesis enzyme N-acyl phosphatidylethanolamine phospholipase D are all found in the 
human and rodent uterus (MacCarrone et al., 2000; Taylor et al., 2010). FAAH and N-acyl 
phosphatidylethanolamine phospholipase D are also found in the ovaries (El-Talatini et al., 2009). Serum 
AEA and FAAH content and activity are also highest during the zygote implantation window in humans 
(Lazzarin et al., 2004). Circulating AEA levels also drop during pregnancy followed by a surge of AEA 
near labor (Habayeb et al., 2004). Lastly, increased AEA or treatment via cannabinoid agonists are linked 
to miscarriages in humans (Habayeb et al., 2008) and implantation or embryonic development disruptions 
in rodents (Schmid et al., 1997; Yang et al., 1996). As with androgens, the endocannabinoid system 
appears to down-regulate LH and GnRH and thereby modulate the release of estrogens. Ovariectomized 
(OVX) female rats show decreased serum LH levels following acute THC administration, which is 
reversed by GnRH administration (Tyrey, 1980; Dalterio et al., 1983). AEA similarly reduced LH levels in 
OVX females, and its effects were reversible with estradiol, and that effect of estradiol could be blocked 
by the CB1R inverse agonist AM-251 (Scorticati et al., 2004). In the limbic forebrain, amygdala and 
hippocampus, OVX itself reduced CB1R density, which was reversible via estradiol administration, while 
the opposite held for the hypothalamus (Riebe et al., 2010; Rodriguez de Fonseca et al., 1994). In the 
mouse uterus, FAAH activity is reduced by estrogens (MacCarrone et al., 2000), and a CB1R antagonist 
reversed the anxiolytic effect of estradiol in rats, while the FAAH inhibitor URB 597 caused an anxiolytic 
response similar to that produced by estradiol (Hill, Karacabeyli and Gorzalka, 2007). This suggests that 
the endocannabinoid system is recruited by estradiol in some of its effects and can down-regulate FAAH 
activity in the CNS (Gorzalka and Dang, 2012). To further complicate matters, estradiol may also directly 
impact endocannabinoid synthesis, as evinced by estradiol treatment in OVX female rats who showed 
increased levels of synthesized AEA in the medial basal hypothalamus (Scorticati et al., 2004). Thus, as 
is the case with androgens and the endocannabinoid system, estrogens and the endocannabinoid system 
have a bidirectional interaction.  
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CB1R density in the brain appears to fluctuate during the estrous and menstrual cycle. In 
humans, circulating AEA levels are highest while ovulating and lower during the luteal phase. AEA levels 
positively correlated with FSH, LH and serum estradiol, but not with progesterone (El-Talatini et al., 2010; 
Habayeb et al., 2004). Conversely, in female rats, 2-AG and AEA levels are highest during diestrus and 
lowest during estrus in the hypothalamus, while showing an opposite trend in the anterior pituitary 
(Gonzalez et al., 2000; Bradshaw et al., 2006). CBR receptor density was highest during diestrus and 
lowest during estrus for female rats in the mediobasal hypothalamus. Meanwhile, in the limbic forebrain, 
the CBR affinity for cannabinoids was highest during diestrus and lowest during estrus, although the 
densities did not fluctuate (Rodriguez de Fonseca et al., 1994). In the anterior pituitary, CB1R mRNA 
transcript levels are highest at diestrus and lowest at estrus (Gonzalez et al., 2000). The disparity within 
the above results may be a consequence of measuring central versus serum endocannabinoid levels. It 
could be that the endocannabinoid system helps regulate the estrous or menstrual cycle, and that central 
changes in that system come before changes in peripheral endocannabinoid and estrogen content 
(Gorzalka and Dang, 2012).  
Progesterone is a hormone found in both men and women, which is converted into testosterone 
and estrogen. Low acute doses of THC increased sexual receptivity and proceptivity, while high doses 
decreased sexual receptivity in female hamsters (Turley and Floody, 1981; Gordon et al., 1978). The 
increase in sexual receptivity from THC is also blocked by administration of either a progesterone 
antagonist, a progesterone receptor expression suppressant or blockade of DA receptors (Mani et al., 
2001). Conversely, sexual receptivity and proceptivity is reduced by CB1R agonists and increased by 
CB1R antagonists in female rats (Ferrari et al., 2000; Lopez et al., 2009). These differential results may 
be due to the use of different species, CB1R agonists and testing apparatuses. On the other hand, the 
CB1R antagonist rimonabant blocks the facilitating effects of both progesterone and DA on female sexual 
behavior. Finally, an antisense D1 receptor nucleotide blocks the sexual effects of THC and 
progesterone. Endocannabinoid activity can also attenuate the release of progesterone from the corpus 
luteum (a hormone-secreting structure in the ovary). Pregnant rats given chronic AEA had lower serum 
progesterone and LH levels (Habayeb et al., 2002). Serum progesterone, corpus lutetium LH receptor 
mRNA and LH receptor density are all reduced following CB1R or CB2R agonists in sheep as well 
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(Tsutahara et al., 2011). Much like androgens and estrogens, progesterone can also regulate 
endocannabinoid signaling. For instance, FAAH expression is increased by progesterone in human 
lymphoma U937 cells, and an interaction between progesterone and the transcription factor promoter 
region of the faah gene causes up-regulation of FAAH expression in T cells (Maccarrone et al., 2001, 
Maccarrone et al., 2003; Maccarrone et al., 2004). Conversely, FAAH activity is down-regulated by 
progesterone in the mouse uterus (MacCarrone et al., 2000). These results collectively suggest a 
bidirectional interaction between progesterone and endocannabinoids which is also associated with 
dopaminergic signaling.  
 
1.3 Biphasic Effects of Cannabinoids  
While initiation of marijuana use may sometimes be to relieve symptoms of anxiety, use can also cause 
symptoms of anxiety, and even lead to the development of mood disorders. The relationship between 
anxiety and cannabis may be complex as a result of bidirectional effects of cannabinoids on the brain. 
Cannabis has bimodal effects on various behaviors. These include anxiety (Marco et al., 2004), locomotor 
and exploratory activity (Genn et al., 2004; McGregor et al., 1996), motivational processing (Maldonado, 
2002), feeding behavior (Bellocchio et al., 2010; Wiley et al., 2005), and novelty seeking (Lafenetre et al., 
2009). 
 
1.3.1 Behavioral Effects 
THC and CP55,940 have both demonstrated biphasic behavioral effects in rats (Table 1). CP55,940 is a 
CBR agonist which binds to the brain CB1R with high affinity, and to CB2R with lower affinity (Herkenham 
et al., 1991). In fact, CP55,940 is approximately 30 times more potent than THC (Little et al., 1988). Low 
doses of THC or CP55,940 have elicited anxiolytic-like effects on the elevated plus-maze (EPM).  
The EPM consists of two opposite open arms and two enclosed arms extended from a common 
central platform based on a design validated by Lister (1987). In humans, anxiety disorders are broadly 
categorized by both symptomology and responsiveness to psychological and/or pharmacological 
treatment.  Ethologically motivated defensive responses in animals serve as homologous or analogous 
means of studying anxiety in an animal model via providing similar changes to behavior and physiology 
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following fear and painful stimuli (Blanchard & Blanchard, 1989).  The elevated plus maze (EPM) is the 
most used test to validate anxiolytic or anxiogenic effects of pharmacological compounds, drugs of abuse, 
and hormones (Walf & Frye, 2007). utilizes an approach-avoidance conflict. Rodents have an 
unconditioned proclivity toward dark and enclosed spaces (approach) and fear of open spaces and 
heights (avoidance) (Barnett, 1975).  Therefore, the key difference in human and rodent models of 
anxiety is that in rodents, research taps into responses in rodents that are adaptive for current conditions, 
while in humans’ anxiety disorders are by definition maladaptive and pathological responses (Bailey & 
Crawley, 2009).  The EPM has well-established face, construct and predictive validity as evinced by 
numerous assessments of such and the thousands of studies which utilized this tool to establish anxiety-
effects of compounds at the preclinical level (Frye et al., 2000; File et al., 1994; Rodgers et al., 1999; 
Pellow et al., 1985). 
Anxiolytic-like responses to low doses of THC or CP55,940 on the EPM are characterized by an 
increase in the percent of total entries and percent of time spent in the open arms (Rubino et al., 2008; 
Braida et al., 2007; Rubino et al., 2007; Marco et al., 2004). Conversely, a higher dose of THC or 
CP55,940 has anxiogenic-like effects on the EPM (Rubino et al., 2008; Schramm-Saptya et al., 2007; 
Marco et al., 2004; Marin et al., 2003; Arevalo et al., 2001; Onaivi et al., 1990). 
Other anxiety tests have also shown biphasic effects of THC and CP55,940. A low dose of THC 
or CP55,940 causes an anxiolytic effect in the light-dark or social interaction tests (Braida et al., 2007; 
Berrendero and Maldonado, 2002; Genn et al., 2004). Meanwhile, a high dose of THC or CP55,940 has 
elicited anxiogenic-like responses in the light-dark, holeboard and social interaction tests (Schramm-
Saptya et al., 2007; Marco et al., 2004; Genn et al., 2004; Biscaia et al., 2003; Marin et al., 2003; Arevalo 
et al., 2001; Navarro et al., 1993).  Finally, sexual behavior has also responded in a biphasic manner 
(Ferrari et al., 2000; Lopez et al., 2009; Gordon et al., 1978). 
Biphasic effects of THC and CP55,940 have also been observed in the open-field paradigm and 
other locomotor assessments (Table 2). THC induces a dose-related suppression of ambulation 
(horizontal activity) and rearing (vertical activity). Low doses of THC increase locomotor activity to more 
than controls, while higher doses of THC induce locomotor suppression (Craft et al., 2012; Jarbe et al., 
2002; Tseng and Craft, 2001). THC also produces a dose-dependent increase in circling behavior, while 
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latency to leave the starting area in the center of the field is significantly elevated by 5.6 mg/kg THC 
(Jarbe et al., 2002). The same trend has been observed in CP55,940 treatment. A low dose of CP55,940 
(10 micrograms/kg) causes locomotor stimulation, while a high dose (100 microgram/kg) causes profound 
hypoactivity (McGregor et al., 1996). Other studies have found similar results, with ambulation and rearing 
frequency decreasing in a dose-dependent manner (Genn et al., 2004; Kosiorek et al., 2003; Romero et 
al., 2002; Tseng and Craft, 2001). 
 
Table 1.  
Acute effects of the CB1/2R agonists ∆9-THC and CP55,940 on the anxiety behavior of rats on the 
elevated plus-maze. 
Compound Anxiolytic-like Effects Anxiogenic-like Effects Reference
1-10 mg/kg Onaivi et al., 1990 
 
0.5-2.5 mg/kg Schramm-Saptya et al., 2007
0.075-1.5 mg/kg Rubino et al., 2007
0.075-0.75 mg/kg Braida et al., 2007
0.075 - 0.125 mg/kg Arevalo et al. 2001
0.075 mg/kg Marin et al., 2003
0.001 mg/kg 0.05 mg/kg Marco et al., 2004
∆9-THC
CP 55,940 
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Table 2. 
 Effects of acute ∆9-THC or CP55,940 on adult rat locomotor behavior; decreases in locomotion are 
dose-dependent. 
Compound Decreased Locomotion Increased Locomotion Reference
5-20 mg/kg 1.25-5 mg/kg Craft et al., 2012
10 mg/kg 1-3 mg/kg Tseng and Craft, 2001
1-5.6 mg/kg 0.56 mg/kg Jarbe et al., 2002
0.1 mg/kg 0.01 mg/kg McGregor et al., 1996
0.2-0.6 mg/kg Romero et al., 2002
0.025-0.25 mg/kg Kosiorek et al., 2003
0.1, 0.3, 0.56 mg/kg Tseng and Craft, 2001
0.04 mg/kg Genn et al., 2004 
CP 55,940 
∆9-THC
 
  
1.3.2 Biochemical Effects 
The biphasic behavioral effects of THC are paralleled by biphasic activity at the biochemical level. An 
acute, low dose (0.075-1.5 mg/kg, intraperitonial (IP)) of THC (seen on the EPM) causes anxiolytic 
behavior on the EPM, which is caused by regional changes to PKA, cFOS, CREB activity, ERK activation 
and Ca2+/calmodulin-dependent protein kinase II (CAMKII) activity (Rubino et al., 2007). In particuv lar, 
cFOS was significantly lowered in the prefrontal cortex and amygdala, while CREB was significantly 
increased in prefrontal cortex and hippocampus. Conversely, high doses of THC or exposure to stressors, 
both of which elicit anxiogenic responses on the EPM, have been correlated to increased cFOS levels 
(Adamec et al., 2012; Ailing et al., 2009; Troakes and Ingram, 2009; Briski and Gillen, 2001; Dayas et al., 
2001).  
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 In a similar vein, a low dose of THC microinjected into the prefrontal cortex and ventral 
hippocampus caused anxiolytic behavior on the EPM, and was accompanied by increased CREB 
activation. Conversely, high doses of THC in the same brain regions had an anxiogenic effect on the EPM 
with decreased CREB activation (Rubino et al., 2008). The THC-induced effects appear to be CB1R 
dependent, as the effects of THC above were reversed by a CB1R antagonist AM251 (Rubino et al., 
2007). Similarly, the CB1R antagonist rimonabant (see Figure 4 for molecular structure) causes increased 
overall PKA-dependent phosphorylation in agreement with increased cAMP levels in the same samples 
(Bellocchio et al., 2013). 
 Receptors with different cannabinoid sensitivity are implicated in the inhibitory/anxiogenic and 
the stimulatory/anxiolytic effects of cannabinoids. CB1Rs may have bidirectional effects on anxiety 
responses as a consequence of their modulatory role in GABA and glutamate (GLU) release across the 
forebrain and amygdala. GABA and GLU are neurotransmitters that impact anxiety levels in contrasting 
ways. Higher GABA levels are anxiolytic while increased GLU is anxiogenic. Cannabinoid analogs may in 
turn produce highly divergent effects by altering GABA and GLU homeostasis (Tambaro and Bortolato, 
2012). 
 GLU is the primary excitatory neurotransmitter in the CNS. GLU transmission is enhanced by 
stress, and stress is a critical variable in the development of mood and anxiety disorders (Simon and 
Gorman, 2006). CB1R-induced inhibition of GLU release has been linked to anxiolytic effects (Lisboa et 
al., 2008; Hoffman et al., 2010). GABA is the primary inhibitory neurotransmitter in the mammalian CNS. 
Benzodiazepines which increase GABAergic transmission are among the main drugs used to treat 
anxiety disorders alongside 5-HT agonists and 5-HT reuptake inhibitors (Millan, 2003). THC and the 
CB1R agonist WIN55,212-2 were both recently shown to inhibit GABA release, which strongly suggests a 
role of CB1R activation in GABA inhibition (Laaris et al., 2010; Hajos et al., 2001). Thus, it is 
hypothesized that CB1R activation on GABAergic neurons decreases GABAergic transmission and 
thereby causes an anxiogenic response. WIN 55,212-2 is a great example of one compound that 
differentially impacts GABA and GLU transmission, and therefore impacts anxiety-like behavior, as WIN 
55,212-2 is far less potent in reducing GLUergic transmission than in inhibition of GABAergic currents. In 
sum, cannabinoids play a bi-directional role in anxiety likely in part because cannabinoids can impact the 
35 
 
 
equilibrium between GLUergic and GABAergic neurotransmission (Figure 12, Piomelli, 2003; Laaris et al., 
2010; Hajos et al., 2001). 
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1.4 Sex Differences 
1.4.1 Sex Differences in Human Cannabis Abuse and Anxiety 
Another key variable in understanding the effects of cannabis is sex. Drug abuse or dependence 
disorders are 2-3 times more common among adult American men than women (Becker and Hu, 2008). 
Similarly, more men than women use cannabis and seek drug treatment in Europe (EMCDDA, 2005). 
However, drug abuse in women is on the rise (Greenfield et al., 2010). The current rate of higher drug 
abuse in men than women may reflect a difference in opportunity rather than vulnerability to drug use, as 
Figure 12. Regulation of presynaptic ion channel activities by CB1Rs. (A) At synapses between GABA 
interneurons and pyramidal cells in the hippocampus, activation of CB1R receptors initiates the following 
intracellular events: 1) activation of G-protein –  subunits 2) closure of voltage-gated Ca2+ channels 3) 
inhibition of GABA release. (B) At Purkinje cell synapses in the cerebellum, CB1R activation: 1) engages 
G-protein -subunits that 2) cause the opening of K+ channels; the resulting membrane hyperpolarization 
can 3) reduce Ca2+ entry and inhibit glutamate release (Figure 12 adapted from Piomelli, 2003).  
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the rate of escalation of drug use and difficulty to quit is greater among women than men. Specifically, 
Van Etten al. showed that while males are more likely to have had the opportunity to use drugs of abuse, 
males and females were equally likely to use these drugs once opportunity had occurred (1999). 
However, following drug initiation, the patterns of drug use and the effects of the drug differ between men 
and women (Kelly et al., 2006; Gunter et al., 2006). Additionally, although women initially consume lower 
doses of an abused drug, they become addicted faster and relapse more often following abstinence 
(Becker and Hu, 2008; Hernandez-Avila et al., 2004). Sex differences are additionally evident during 
other phases of the substance abuse cycle, such as escalation and dysregulation (Caroll et al., 2004). 
In terms of cannabis use, American males initiate marijuana use at a younger age than females 
(16.4 vs 17.6 years; SAMSHA, 2004), and are more likely than women to use marijuana on a daily basis 
(2.0% vs 0.7%; Gfroerer et al., 2002). However, treatment for marijuana-use disorder is sought after 
significantly fewer years of use among women than men (Hernandez-Avila et al., 2004), and women 
report more withdrawal symptoms than men when attempting to quit (Copersino et al., 2010; Levin et al., 
2010). The DSM-IV does not recognize cannabis withdrawal since it lacks clinical significance, however, 
marijuana users often display a withdrawal syndrome and attempts at relief of said syndrome that lead to 
relapse during cessation attempts (Levin, 2010).  
Some substances of abuse such as stimulants show a link between use and phase of the 
menstrual cycle (Becker and Hu, 2008). However, no such relationship has been observed between 
menstrual phase and use of or response to marijuana, except in the case of women with severe 
premenstrual dysphoric disorder or premenstrual syndrome (Griffin et al., 1986, Terner and de Wit, 2006). 
Among women with premenstrual dysphoria, increased marijuana intake in female smokers was 
associated with significant increases in reported anger, anxiety, mood liability, depression, impaired social 
function and irritability (Mello and Mendelson, 1985). Lastly, women demonstrate neuropsychological 
effects of marijuana which are sex dependent. For example, visual-spatial memory is more impaired in 
women who smoke heavily compared to light smokers, while no difference is observed in men (Pope et 
al., 1997).  
Sex differences exist in the anxiety disorders which frequently accompany cannabis addiction. 
The pathological expression of anxiety results in a consistent apprehension towards vaguely defined 
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possibilities of negative outcomes in the future (Nutt et al., 2008). Anxiety disorders are the most 
prevalent class of mental disorders in the United States. One in five adults suffers from an anxiety 
disorder, which is approximately ~40 million American adults (~18% of US adults; Kessler et al., 2005). 
Women are significantly more likely to develop an anxiety disorder during their lifetime than are men 
(Bruce et al., 2005). Lifetime prevalence rates for any anxiety disorder are 30.5% and 19.2 % among 
women and men respectively (Kessler et al., 1994). Meanwhile, current prevalence is higher among 
women than men for most anxiety disorders. These include generalized anxiety disorder (6.6% vs. 3.6%), 
panic disorder (5.0% vs. 2.0%), post-traumatic stress disorder (10.4% vs. 5.0%), agoraphobia (7.0% vs 
3.5%) and specific phobia (15.7% vs. 6.7%) in women versus men (Kessler et al., 1995). Furthermore, 
44.8% of women compared to 34.2% of men with a lifetime diagnosis of an anxiety disorder meet criteria 
for an additional anxiety disorder, and women suffer a greater illness burden from anxiety disorders than 
do men (McClean et al., 2011). Finally, sex differences are evident in those who both use marijuana and 
have a mood disorder. Teenage use of marijuana at least once per week predicts a two-fold increase in 
later depression and anxiety. In particular, daily marijuana use among women under the age of twenty is 
associated with an over fivefold increase in the odds of developing depression or anxiety compared to 
teenage males (Patton, 2002). 
 
1.4.2 Sex Differences in Rodent Studies of Cannabinoids 
Female rodents show heightened sensitivity to the rewarding properties of drugs of abuse compared to 
males, which is attributed to DA-enhancement via oestrogen (Segarra, Agosto-Rivera and Febo 2010; 
Silverman and Koenig 2007). For instance, female rodents show a greater voluntary intake of alcohol 
(Eriksson, 1968a; Eriksson, 1968b), caffeine (Heppner et al., 1986), cocaine (Matthews et al., 1999; 
Morse, Erwin and Jones, 1993), heroin (Carroll et al., 2001), fentanyl (Klein et al., 1997) and morphine 
(Alexander et al., 1978; Hill and Powell, 1976) than do males.  
Although it is a small, growing body of evidence, sex differences are apparent in the behavioral 
effects of cannabinoids. THC discrimination is acquired in approximately 1/3 fewer sessions in female 
versus male mice (Wiley et al., 2011b). Male rats show slower acquisition of cannabinoid self-
administration and less drug intake than females (Fattore et al., 2007). This is accompanied by a lower 
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response rate for the cannabinoid when exposed to acute drug and cue primings after extinction (Fattore 
et al., 2007). Additionally, cannabinoid-induced impairments in spatial learning are also greater in female 
versus male rats (Cha et al., 2010). Cannabinoids also enhance sexual behavior in female rodents but 
inhibit it in males (Gorzalka et al., 2010). 
Sex differences are evident in locomotor effects of cannabinoids. Untreated female rats show 
greater locomotor activity at baseline than do males (Craft et al., 2012). Female rats show greater effects 
of THC or CP55,940 on warm water tail withdrawal, radiant heat tail flick, paw pressure, catalepsy bar 
and spontaneous locomotor activity tests and sedation assessments than do males (Craft et al., 2012; 
Wiley et al., 2007; Tseng et al., 2004; Wiley, 2003; Romero et al., 2002; Tseng and Craft, 2001). Female 
rodents are more sensitive than are males to the biphasic effects of cannabinoids on locomotion– i.e. 
increased locomotion at lower doses and decreased locomotion at higher doses (Craft et al., 2012; Tseng 
and Craft, 2001; Wiley, 2003). It is interesting to note that exposure to a high-fat diet profoundly 
decreases female rat sensitivity to THC-induced motor and antinociceptive effects, while diet has no 
effect in males (Wiley et al., 2011a). The sex-specific changes in motor activity induced by cannabinoids 
are important because antinociception, which is often measured as lengthening of latency to respond, 
may be caused by drug-induced suppression of motor activity (Craft et al., 2012; Wiley et al., 2011a).  
Other effects of cannabinoids have also shown sex-differences. While THC levels in brain tissue 
and serum levels of THC and its metabolites are similar in both sexes post-injection, THC metabolites in 
brain tissue are higher in females than males (Tseng et al., 2004). Furthermore, THC antagonism via 
rimonabant in females is 10 times more potent on nociceptive tests, its’ affinity for the CB1R is 0.5 to 1 
mol/kg higher, and is effective at differential time points post-injection compared to males (Craft et al., 
2012).  
Sex differences are also seen in the long-term impact of THC and CP55,940. Chronic THC 
exposure produces increased desensitization and down-regulation of CB1Rs in the brains of female 
versus male adolescent rats (Burston et al., 2010). Similarly, female rats show a significant reduction of 
CB1R density and function in the amygdala, nucleus accumbens and ventral tegmental area, compared 
to significant alteration of amygdala and hippocampal formation in male rats following THC exposure 
during adolescence (Rubino, et al., 2008). Male and female rats which had been chronically treated with 
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THC showed no change on EPM or OF performance as adults (Rubino, et al., 2008). However, female 
rats which had received THC as adolescents showed depressive behavior in the forced swim test and 
anhedonia in the sucrose preference test, while there was no lasting drug effect in males (Rubino et al., 
2008). These sex differences in behavior were supported by the fact that only female rats had low CREB 
activity in the hippocampal formation and prefrontal cortex and high CREB activity in the nucleus 
accumbens after adolescent THC exposure (Rubino et al., 2008). Similarly, among adolescent rats 
treated chronically with CP55,940, only females showed a significant increase in the percent of time and 
entries into the open arms of the maze as adults compared to males that showed no effect of previous 
treatment (Mateos et al., 2011). 
Sex differences are apparent in the effects of chronic stress. Females show an increase in 
hippocampal CB1R following chronic stress, while males show a decrease. This effect does not depend 
upon hormonal status, as gonadectomized rats showed the same effect (Reich et al., 2009). Similarly, 
sex differences were seen in the effects of acute and chronic THC in mice. Acute THC increased 
locomotor activity in female, but not male, mice. Additionally, female mice continued to show greater 
stimulatory sensitivity to THC than males after multiple doses, although higher doses were required to 
produce the increases (Wiley, 2003). 
Ovarian hormones are also likely to play a key role in the sex differences seen in the effects of 
exogenous cannabinoids on anxiety. For instance, in female rats, the HPA axis is most sensitive to stress 
during proestrous (Viau & Meaney, 1991).  Similarly, a study that used individual housing as a stress 
exposure showed that individually housed female mice showed greater anxiety-like behaviors than those 
in group housing.  However, proestrus mice were less sensitive to these effects than estrus and diestrus 
females (Palanza et al., 2001).  Meanwhile, chronic THC has been shown to delay sexual maturation in 
female rats (Field & Tyrey, 1984).  Additionally, while chronic THC had no effect on length of estrous 
cycle or mating activity, although it did reduce term pregnancies by 32-68% which varied by dose; this 
effect dissipated after a 30-day recovery period (Kostellow et al., 1980).  Furthermore, female estrous 
stage impacts THC-induced antinociception. Females in late proestrus to estrus are most sensitive to 
THC, and thereby show the greatest discrepancy from males (Craft and Leitl, 2008; Wakley and Craft, 
2011). Estradiol enhances both THC-induced nociception and WIN55,2-2-2 self-administration in OVX 
41 
 
 
female rats (Fattore et al., 2010b). Furthermore, estradiol also attenuates cannabinoid-induced disruption 
of acquisition and performance of an operant task in OVX rats (Daniel et al., 2002; Winsauer et al., 2011). 
Estradiol also enhances the antinociceptive but not the motor effects of THC in gonadectomized females.  
In normal females, THC had greater pain effects in estrous than diestrous females (Craft & Leitl, 2008). 
Thus ovarian hormones appear to play a significant role in sex-differences in the effects of cannabinoids. 
The differential effects of exogenous cannabinoids may be the consequence of differences in 
brain endocannabinoid systems between the sexes.  The CB1R reaches peak levels in the developing 
rodent brain in females before males: postnatal day (PND) 30 versus PND 40 respectively. Additionally, 
the endocannabinoid system may be involved in neuronal migration and brain development, processes 
that also exhibit sexual dimorphism (Berrendero et al., 1998; Romero et al., 1997). A recent study showed 
significantly lower CB1R density in the prefrontal cortex and amygdala of cycling female rats compared to 
male and OVX females, with no difference in CB1R density seen in the caudate-putamen, nucleus 
accumbens and hippocampus (Castelli et al., 2014). Levels of endocannabinoids and their metabolic 
enzymes also differ. For example, male rodent amygdalas show higher levels of AEA and 2-AG, while 
female amygdalas have higher concentrations of their primary metabolic enzymes, monoacylglycerol 
lipase (MAGL) and FAAH respectively (Krebs-Kraft et al., 2010). Sex differences are also evident in 
CB1R binding (Riebe et al., 2010), and receptor numbers by brain region, the latter fluctuating across the 
estrous cycle in females (Gonzalez et al., 2000; Rodriguez de Fonseca et al., 1994). 
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1.5 Specific Aims (Figure 13) 
Rationale: Women are 2 times more likely to suffer from an anxiety disorder than men (Kessler et al., 
2005), and those with an anxiety disorder are 2-3 times more likely than the general populace to have a 
comorbid substance abuse disorder (Kessler et al., 1994). Emerging evidence shows that women 
become addicted faster and relapse more often following cannabis abstinence than do men (Becker and 
Hu, 2008; Hernandez-Avila et al., 2004). However, there exists little preclinical research elucidating the 
biochemical mechanisms that underly these sex differences.      
 
Hypothesis: in females, acute administration of CP55,940 will have more profound behavioral and 
biochemical effects on anxiety-like behavior than in males.  
 
Aim 1: Sex differences in bi-phasic behavioral effects  
To test the hypothesis that a low-dose of CP55,940 will be anxiolytic, while higher doses will be 
anxiogenic, and that this effect will be more pronounced in females than males. The testing apparatus for 
anxiety assessment is the elevated plus-maze (Figure 13A). 
 
Aim 2: Sex differences in protein changes  
To test the hypothesis that CP55,940 treatment alters protein levels in brain regions involved in anxiety 
more significantly in females than males. Brain regions examined will include the prefrontal cortex, 
nucleus accumbens, caudate-putamen, amygdala and hippocampus.  Higher induction of parts of the 
PKA pathway, including an increase in DARPP-32, ERK and c-FOS and a drop in p-CREB will 
accompany an anxiogenic behavioral response. Conversely, decreased phosphorylation of p-ERK and 
cFOS, with a rise in DARPP-32 and p-CREB will underlie anxiolytic behaviors (Figure 13A).  
  
Aim 3: Sex differences in the role of CB1R 
To test the hypothesis that sexually dimorphic CB1R activation underlies sex differences in CP55,940-
induced changes to anxiety-like behaviors and intracellular responses. CP55,940-induced CB1R 
activation will be antagonized via the CB1R antagonist rimonabant (Figure 13B).  
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Figure 13. Summary of hypotheses tested in adult male and female Wistar rats. These include the 
hypotheses that: (A|1) a low-dose of CP55,940 is anxiolytic, while higher doses are anxiogenic, and 
this effect will be more pronounced in females than males (A|2) CP55,940 treatment alters protein 
levels in brain regions involved in anxiety more significantly in females than males. High doses of 
CP55,940 will cause increases in p-DARPP-32, p-ERK and cFOS levels and a reduction in p-CREB, 
while low doses will elicit increases in p-DARPP-32 and p-CREB with a reduction in p-ERK and 
cFOS. (B) Sexually dimorphic CB1R activation underlies sex differences in CP55,940-induced 
changes to anxiety-like behaviors and intracellular responses, thus pretreatment with the CB1R 
antagonist rimonabant will prevent CP55,940-induced changes in anxiety-like behavior and protein 
levels. 
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II.  METHODS 
2.1 Subjects 
Experiments were performed on adult (PND 60) male and female Wistar rats weighing 250–300 g. Rats 
were housed in standard laboratory cages, each containing two individuals. Food and water were 
available ad libitum in an environmentally controlled animal facility with a 12-hour light/dark cycle, with 
lights on from 0800 – 2000 hours. All animals were quarantined for one week upon arrival to the animal 
facility, and then handled for seven days prior to testing. This study was approved by the Institutional 
Animal Care and Use Committee of Hunter College of the City University of New York and complied with 
the guidelines of the Committee for Research and Ethical Issues of IASP published in PAIN, 16 (1983) 
109-110. 
 
2.2 Researchers 
It was recently discovered that exposure to male but not female researchers produces stress in rodents 
which skews behavioral results (Sorge et al., 2014). As such, we believe it is important to disclose this 
information in our methods to increase replicability: a female researcher tamed and tested the animals 
and a male colleague sacrificed the animals.  
 
2.3 Pharmacological Treatment 
The CB1R and CB2R analog CP55,940 (Tocris, USA) and the CB1R antagonist rimonabant (Sigma, 
Poole, UK) were dissolved in ethanol (BDH, Poole, UK) and cremophor (Sigma, Poole, UK). Saline was 
then added (1:1:18) for a volume of 1 ml/kg body weight. Stock solutions of 3.0 mg/kg rimonabant and 1.0 
mg/kg CP55,940 were aliquoted and frozen at -20 degrees, and then diluted to the appropriate dose on 
testing day. Control animals received equal volume injections of the corresponding vehicle. 
In the dose response curve (DRC), male and female rats were divided into groups according to: 
1) sex and 2) CP55,940 treatment (2 sexes x 5 doses). There were five treatment groups of CP55,940: 0, 
0.001, 0.01, 0.075, and 0.125 mg/kg, IP. These doses of CP55,940 were selected on the basis of 
previous studies that demonstrated anxiety-like effects of CP55,940 in male rats (Marco et al., 2004; 
Marin et al., 2003; Kosiorek et al., 2003; McGregor et al., 1996).  In the CB1R antagonism study, male 
45 
 
 
and female rats were divided into groups according to: 1) sex and 2) treatment (2 sexes x 4 drug 
conditions). There were four treatment groups: vehicle + vehicle, 0.075 mg/kg CP55,940 + vehicle, 3.0 
mg/kg RIM + vehicle and 3.0 mg/kg RIM + 0.075 mg/kg CP55,940, IP. The 0.075 mg/kg CP55,940 dose 
was used because it was the most behaviorally efficacious dose as evinced by causing the largest 
change in anxiety levels in the DRC. The animals received injection of the first compound, placed back 
into their home cages, received the second injection 30 minutes later, and were then tested on the 
elevated plus-maze for 10 minutes 30 minutes after the last injection. In both studies, all rats were 
exposed to one pharmacological treatment only and received the same number of injections, ensuring 
that appropriate vehicle controls were present. The order in which animals were exposed to the doses 
was randomized. 30 minutes after injection, animals were placed on the elevated plus-maze for 10 
minutes and their behaviors were recorded using Med Associates behavioral tracking software (St 
Albans, VT, USA).  
 
 
2.4 Behavioral Studies 
Elevated plus-maze: The elevated plus-maze (EPM) Model HEMP1001 consists of two opposite open 
arms (50.17 x 10.8 cm) and two enclosed arms (50.17 x 10.8 x 40.01 cm) extended from a common 
central platform (10 x 10 cm) based on a design validated by Lister (1987). The apparatus features 
Plexiglass walls and floors with a floor photo beam sensor system to quantify anxiety. The EPM is 
elevated to a height of 33.5 cm above floor level and placed in a small room that is lit with low light (150 
lux). Animals were brought into the behavioral testing room in their group home cages and left 
undisturbed for 2 hours prior to behavioral testing. After the injection in the testing room, animals were 
returned to their home cage. Thirty minutes post-injection, animals were placed individually onto the 
center of the apparatus facing an open arm, spent 10 minutes in this apparatus and were videotaped 
during the session. Med Associates behavioral tracking software (St Albans, VT, USA) recorded the 
number of entries into and time spent on each arm. The maze was wiped clean with diluted alcohol and 
dried after each trial. All experimental sessions were conducted during the morning time of the light cycle 
(1100-1500 hours). An arm entry was recorded when all four paws of the rat were in the arm. Time spent 
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in each arm and number of open- and closed-arm entries were recorded. Data was expressed as the 
percentage (open or closed time/total time x 100; open or closed entries/total entries x 100). The 
percentage of time spent in the open arms and the percentage of open-arm entries were used as 
measures of anxiety (Hogg, 1996). 
 Seven behaviors were analyzed on the elevated plus maze. Assessment of these behaviors 
commenced the moment that all four paws of the rat were placed on the intersection of the maze, and 
ended when the animal had been on the maze for a total of 10 minutes. The following parameters were 
analyzed: 
 
a. Percent of time spent in the open arms, calculated as the number of seconds spent in the open 
arms of the maze per number of seconds in the open + closed arms of the maze.  
b. Percent of open arm entries, calculated as the number of entries into the open arms of the maze 
per number of entries into open + closed arms. 
c. Percent of open arm pokes, calculated as the number of pokes into the open arms of the mazes 
per number of pokes into the open + closed arms.  
d. Number of open arm end pokes. 
e. Total number of arm entries, calculated as the number of entries into the open + closed arms of 
the maze. 
f. Total distance traveled in centimeters.  
g. Total beam breaks on any location of the maze. 
 
No Estrous Measures: Previous literature indicates a potential role of estrous in anxiety-like behaviors 
and in the effects of cannabinoids (Wakley and Craft, 2011; Fattore et al., 2010b; Daniel et al., 2002; 
Winsauer et al., 2011; Krebs-Kraft et al., 2010; Gonzalez et al., 2000; Rodriguez de Fonseca et al., 1994; 
Craft & Leitl, 2008; Viau & Meaney, 1991; Palanza et al., 2001).  However, as there was no way to 
expose male rodents to an equivelant stressor we did not assess estrous in females as exposing them to 
additional stress could have confounded our sex differences findings.  We plan to include estrous and 
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estrogen measures in future research and compare it to the results of these studies to ensure that vaginal 
smearing does not significantly alter anxiety levels.   
 
2.5 Biochemical Studies 
Protein preparation and measurement: Immediately following the behavioral test, rats were exposed to 
CO2 for three minutes, guillotined, their brains removed, flash frozen in 2-methylbutane (−40° C), and 
stored at −80° C until used as according to Heffner et al., 1980. 1mm thick coronal slices were cut out in a 
matrix (ASI instruments, Warren, MI) and brain regions were dissected on a cold glass plate. The cerebral 
areas extracted included the prefrontal cortex (mPFC), nucleus accumbens (AcbC and AcbSh), caudate 
putamen (medial and lateral striatum), amygdala (CeA and BLA), and hippocampus (CA1 and DG). 
Bregma coordinates were inferred from the brain atlas of Paxinos and Watson (1997) as previously done 
by Li et al., 2009 (see Figure 14). Brain regions were homogenized by using a Polytron handheld 
homogenizer (Kinematica, Luzern, Switzerland) in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM 
EDTA, 10% Glycerol, 1% Triton X-100, 1% Igepal CA-630, 1% sodium dexycholic acid) containing 
phosphatase inhibitors mixture. After 30 min incubation, homogenates were centrifuged at 13,000 rpm for 
15 min at 4° C. Supernatants were then collected and stored at −80° C until used. Total protein content 
was determined using a Bradford kit from Bio-Rad Laboratories (Hercules, CA). 
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Figure 14. Brain areas of rat analyzed in this study: mPFC of prefrontal cortex; AcbC and AcbSh of 
nucleus accumbens; medial striatum, CeA and BLA of amygdala and CA1 and DG of hippocampus. 
Bregma coordinates were inferred from the brain atlas of Paxinos and Wastson (1997). 
 
49 
 
 
Western blot analysis: Protein samples were analyzed by using Western blot as previously described 
(Jenab et al., 2005). Briefly, 40 μg of protein extracts were boiled in Lammeli buffer containing 1% β-
mercaptoethanol for 5 min, ran on SDS-PAGE gels, and transferred to PVDF membranes. After transfer, 
membranes were washed once in 1X TBST, and incubated on a rocker set to low in primary antibody 
overnight at 4° C. Primary antibodies were diluted at a ratio of 1:1000 in 10 ml of TBST + 5% sucrose for 
each PVDF membrane.  Primary antibodies of cFOS (#4384S) phospho-DARPP-32 (Thr34; #12438S) 
and phospho-ERK (#9101S) were purchased from Cell Signaling Technologies (Beverly, MA) and 
phospho-CREB (#06-519) was purchased from Upstate Biotechnology (Lack Placid, NY). For 
normalization of protein levels, all membranes were re-probed with α-tubulin antibody (#sc-8035) from 
Santa Cruz Biotechnology (DBA, Italy) diluted at 1:1000. Membranes were then incubated on a rocker set 
to low for one hour in 10 ul of secondary antibody (Amersham rabbit #NA9340V or mouse NA931V) in 10 
ml of TBST + 5% sucrose. After three washes with Tris-Tween-20 Buffer (TBST; pH = 7.4) antibody 
binding was detected by using an enhanced chemiluminescence kit (GE Amersham Prime# RPN2236; 
Fisher Scientific). Labworks Image Acquisition and Analysis Software (UVP Inc., Upland, CA, USA) was 
employed for obtaining images and for the semi-quantitative digital image analysis of the band of the PCR 
product. To allow comparison between different autoradio- graphic films, the density of the bands was 
expressed as a percentage of the average of control. The value of active phospho-proteins was 
normalized to the amount of total proteins in the same sample and expressed as a percentage of 
controls. 
 
2.6 Data Analysis 
The number of animals used in these studies was estimated based on previous research in our laboratory 
and a power analysis which was confirmed by IACUC to be the minimum number of animals needed to 
provide useful data.  Behavioral studies therefore included a minimum of 8 animals to a maximum of 12 
animals per drug group and sex (see Tables 3 and 4).  Protein analysis on the other hand, included a 
minimum of 4 to a maximum of 6 animals per condition.  Two-way analysis of variance (ANOVA) was 
conducted to determine the effects of dose and sex and followed by Tukey’s post-hoc analysis when 
appropriate to compare overall dose effects. Further comparisons of sex differences within dosing groups 
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were performed via independent samples t-tests. Pearson’s correlations were used to examine the 
interaction between behavioral and biochemical results.  Significance was based on p < 0.05. We report 
standard error (SE) rather than standard deviation (SD) from the mean for two reasons.  First, given the 
sensitivity of anxiety and protein measures from between subjects differences at baseline, we wanted to 
indicate the uncertaintiy around the estimate of the mean measurement, not just a measure of data 
dispersion from the mean as provided by SD.  Second, SE depends on both SD and sample size, and 
therefore reflects information about SD when reporting it. Outliers were removed when they were over 1.5 
box-lengths outside of the I.Q. range for dependent variables. 
 
 
 
 
Table 3.  
Minimum to maximum number of subjects in the CP55,940 dose response curve (n = 5 drug conditions * 
2 sexes * 8-12 animals = 90-120). 
 
Drug Dose Males Females 
Vehicle ( n = 8-12) ( n = 8-12) 
0.001 mg/kg ( n = 8-12) ( n = 8-12) 
0.01 mg/kg ( n = 8-12) ( n = 8-12) 
0.075 mg/kg ( n = 8-12) ( n = 8-12) 
0.125 mg/kg ( n = 8-12) ( n = 8-12) 
Total ( n = 45-60) ( n = 45-60) 
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Table 4.  
Minimum to maximum number of subjects in the CB1R antagonism study (n = 4 drug conditions * 2 sexes 
* 12 animals = 64-96). 
 
Drug Dose Males Females 
Vehicle + Vehicle ( n = 8-12) ( n = 8-12) 
CP55,940 + Vehicle ( n = 8-12) ( n = 8-12) 
3.0 mg/kg RIM + Vehicle ( n = 8-12) ( n = 8-12) 
CP55,940 + 3.0 mg/kg RIM ( n = 8-12) ( n = 8-12) 
Total ( n = 32-48) ( n = 32-48) 
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III. RESULTS 
3.1 Dose Response Curve Results  
3.1.1 Behavioral Results 
3.1.1a Anxiety Measures (Figure 15 & 16) 
A two-way ANOVA (dose x sex) revealed a significant main effect of dose on the percent open arm time 
[F(4, 96) = 5.68, p < 0.001]. The control group spent more time in the open arms than the 0.075 mg/kg 
dose group (p < 0.05). Moreover, rats in the 0.001 mg/kg drug condition spent more time in the open 
arms than the 0.075 mg/kg and 0.125 mg/kg drug treatments (p < 0.01 and p < 0.05 respectively). For a 
summary of all behavioral statistics refer to Table 5.  
 A main effect of treatment and sex was seen on the percent of open arm entries (dose [F(4, 96) = 
8.84, p < 0.001], sex [F(1, 96) = 9.21, p < 0.05]). Control group rats showed a significantly higher percent 
of open arm entries than rats in 0.01 mg/kg, 0.075 mg/kg and 0.125 mg/kg treatment conditions (p < 0.05, 
p < 0.01 and p < 0.01 respectively). The percent of open arm entries in the 0.001mg/kg treated group 
were also significantly higher than rats receiving 0.01 mg/kg, 0.075 mg/kg and 0.125 mg/kg doses (p < 
0.05, p < 0.001 and p < 0.01 respectively). Control condition males had a significantly lower percent of 
open arm entries compared to control group females; [t(19) = 2.65, p < 0.05], (males: M = 16.83, SE = 
3.30; females: M = 27.27, SE = 1.96). Males treated with 0.01 mg/kg CP55,950 also showed significantly 
fewer open arm entries than females of the same group; [t(20) = 2.58, p < 0.05], (males: M = 8.26, SE = 
2.41; females: M = 16.51, SE = 2.10). Lastly, in the 0.075 mg/kg drug condition, the percent open arm 
entries for males was smaller than those of females [t(12.29) = 2.49, p < 0.05], (males: M = 2.55, SE = 
1.16; females: M = 11.42, SE = 3.37).  
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Figure 15. Sex (male ( ) vs female ( )) and dose effect (CB1R- and CB2R-agonist CP55,940) on 
classic anxiety measures in the EPM: A) percent open arm time and B) percent open arm entries in the 
EPM. Outliers were removed when they were over 1.5 box-lengths outside of the I.Q. range for these 
measures. N = 9-11 per group. Two-way ANOVA followed by Tukeys’ post-hoc for overall dose 
comparisons: *p<0.05, **p<0.01, ***p<0.001. Independent-samples t-tests examined sex differences 
within doses: #p<0.05.  
     
 
 A main effect of drug treatment on percent of open arm pokes was observed [F(4, 98) = 4.23, p < 
0.01], where rats treated with 0.001 mg/kg had more pokes than those in 0.075 mg/kg and 0.125 mg/kg 
drug conditions (p < 0.05 and p < 0.05 respectively). A significant main effect of sex was also seen [F(1, 98) 
= 9.55, p < 0.01]. Males treated with 0.01 mg/kg CP55,940 had significantly fewer open arm pokes than 
did females of the same dose condition; [t(20) = 3.23, p < 0.01], (males: M = 7.85, SE = 1.73; females: M 
= 17.30, SE = 2.37).  
 A significant main effect of sex on open arm end pokes was found [F(1, 96) = 8.42, p < 0.01]. 
Control treated males had a greater number of pokes off ends of open arms than did control treated 
females; [t(19) = -2.32, p < 0.05], (males: M = 25.30, SE = 4.51; females: M = 13.73, SE = 2.41). Males 
treated with 0.01 mg/kg of CP55,940 also showed a higher number of pokes than females of the same 
drug group; [t(19) = -3.83, p < 0.01], (males: M = 26.20, SE = 4.10; females: M = 9.91, SE = 1.63).  
 
A
. 
B
. 
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Figure 16. Effect of sex (male ( ) vs female ( )) and the CB1R- and CB2R-selective agonist 
CP55,940 on additional anxiety measures on the EPM: A) percent of pokes into the open arms B) number 
of open arm end pokes on the EPM. Outliers were removed when they were over 1.5 box-lengths outside 
of the I.Q. range for these measures. N = 9-11 per group. Two-way ANOVA followed by Tukeys’ post-hoc 
for overall dose comparisons: *p<0.05. Independent-samples t-tests to examine sex differences within 
doses: #p<0.05, ##p<0.01. 
 
 
3.1.1b Locomotor Measures (Figure 17) 
A main effect of dose on total arm entries was seen [F(4, 97) = 6.89, p < 0.001]. Control rats had 
significantly more total arm entries than the 0.075 mg/kg treatment group (p < 0.05). Total arm entries in 
the 0.125 mg/kg dose condition were significantly lower than the control and 0.001 mg/kg drug groups (p 
< 0.001 and p < 0.01 respectively). A significant main effect of sex was also found [F(1, 97) = 13.55, p < 
0.001], although independent t-tests revealed no sex differences within the dose conditions. 
A two-way ANOVA (dose x sex) revealed a significant effect of dose, sex, and a dose x sex 
interaction on total distance traveled ([F(4, 95) = 5.71, p < 0.001], [F(1, 95) = 22.25, p < 0.001] and [F(4, 95) = 
2.77, p < 0.05] respectively). The 0.125 mg/kg treatment differed from control (p < 0.01), 0.001 mg/kg (p < 
0.05), 0.01 mg/kg (p < 0.001) and 0.075 mg/kg (p < 0.01) dose conditions. In the 0.125 mg/kg drug 
condition, males showed a large decrease in distance traveled in contrast to all other drug conditions. 
Males treated with 0.001 mg/kg showed significantly less distance traveled than females; [t(20) = 2.64, p 
< 0.05], (males: M = 6027.82, SE = 314.42; females: M = 7112.45, SE = 264.27). Similarly, male rats 
B
. 
A
. 
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exposed to 0.01 mg/kg and 0.125 mg/kg of CP55,940 traveled less than females of the same treatment 
groups; 0.01 mg/kg: [t(18) = 2.62, p < 0.05], (males: M = 6623.33, SE = 140.09; females: M = 7365.27, 
SE = 228.58) and 0.125 mg/kg: [t(17) = 2.96, p < 0.01], (males: M = 4006.64, SE = 765.77; females: M = 
6719.10, SE = 504.09).  
 A significant main effect of drug treatment on the number of beam breaks was found [F(4, 93) = 
9.66 p < 0.001]. The 0.125 mg/kg drug group demonstrated significantly fewer beam breaks than control, 
0.001 mg/kg, 0.01 mg/kg and 0.075 mg/kg treatment groups (p < 0.001, p < 0.001, p < 0.01 and p < 0.01 
respectively). Sex also had a significant main effect [F(1, 93) = 31.36, p < 0.001]. Females exhibited more 
beam breaks than males in every dose condition: Control treatment [t(20) = 2.28, p < 0.05], (males: M = 
1203.27, SE = 51.66; females: M = 1352.00, SE = 40.04); 0.001 mg/kg treatment[t(12.45) = 3.94, p < 
0.01], (males: M = 1061.73, SE = 71.16; females: M = 1359.50, SE = 25.23); 0.01 mg/kg treatment 
[t(13.63) = 5.35, p < 0.001], females: M = 1318.63, SE = 22.42) males: M = 1068.80, SE = 40.99); 0.075 
mg/kg treatment [t(18) = 2.13, p < 0.05], (males: M = 1027.44, SE = 64.23), females: M = 1228.09, SE = 
66.85) and 0.125 mg/kg treatment [t(20) = 2.47, p < 0.05], (males: M = 658.09, SE = 129.36; females; M = 
1080.09, SE = 111.36).  
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Figure 17. Effect of sex (male ( ) vs female ( )) and the CB1R- and CB2R-selective agonist 
CP55,940 on locomotor behavior in the EPM: A) total number of arm entries B) distance traveled in 
centimeters C) total number of beam breaks. Outliers were removed when they were over 1.5 box-lengths 
outside of the I.Q. range for this measure. N = 8-11 per group. Two-way ANOVA followed by Tukeys’ 
post-hoc for overall dose comparisons: *p<0.05, **p<0.01, ***p<0.001. Independent-samples t-tests to 
examine sex differences within doses: #p<0.05, ##p<0.01, ###p<0.001. 
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3.1.2 Biochemical Results  
3.1.2a: Thr34 phospho-DARPP-32 (Figure 18) 
A significant effect of drug treatment on DARPP-32(Thr34) levels in the nucleus accumbens (NAC) was 
observed [F(3, 24) =7.09, p < 0.01]. DARPP-32 amounts rose significantly in the 0.125 mg/kg compared to 
the 0.001 mg/kg, 0.01 mg/kg and 0.075 mg/kg dose conditions (p < 0.05, p < 0.05 and p < 0.01) [See 
table 6 for a summary of all protein-related statistics]. 
Dose [F(3, 24) = 9.21, p < 0.0001], sex [F(1, 24) = 26.69, p < 0.0001], and the dose x sex interaction [F(3, 
24) = 13.15, p < 0.0001] were significant in the caudate putamen (CPU). DARPP-32 levels were higher in 
males and lower in females in the 0.125 mg/kg treatment compared to all other drug conditions: 0.0001 
mg/kg, 0.01 mg/kg and 0.075 mg/kg (p < 0.01 for all comaprisons). Within the 0.125 mg/kg treatment 
group, the sharp increase in DARPP-32 levels in males was significantly different from the dramatic 
decrease in DARPP-32 levels in females; [t(3.06) = -4.53, p < 0.05] (males: M = 1356.26, SE = 308.23, 
females: M = -45.77, SE = 30.64).  
 In the hippocampus (HIP), only sex had a significant main effect [F(1, 24) = 4.74, p < 0.05], 
although independent samples t-tests failed to reveal any sex differences within each dose. Finally, no 
significant dose or sex effects were found in DARPP-32 levels of the medial prefrontal cortex (mPFC) or 
amygdala (AMYG).  
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Figure 18. Phospho-DARPP-32 (Thr34) protein levels (measured at 32 kDA) in the mPFC (A) NAC (B) 
CPU (C) AMYG (D) and HIP (E) of male ( ) and female ( ) rats after EPM testing. Phosphorylated 
protein levels are expressed as a ratio to their respective total protein levels (normalized to α-tubulin, 55 
kDA; SEM). Results are expressed as the percentage p-DARPP-32 vs saline. Outliers were removed 
when they were over 1.5 box-lengths outside of the I.Q. range for this measure. N = 4 per group. Two-
way ANOVA followed by Tukeys’ post-hoc for overall dose comparisons: *p<0.05. **p<0.01. Independent-
samples t-tests to examine sex differences within doses: #p<0.05.  
A. mPFC D.  AMYG 
C. CPU
+. 
B. NAC. E. HIP 
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3.1.2b: phospho-ERK (Figure 19) 
A significant effect of sex was observed in the mPFC [F(1, 24) = 6.12, p < 0.05], although independent 
samples t-tests assessing sex differences within each dose condition failed to reach significance. 
Similarly, sex had a significant effect on p-ERK levels of the CPU [F(1, 24) = 8.75, p < 0.01]. In the 0.125 
mg/kg treatment group of the CPU, p-ERK increased significantly in males while it dropped females [t(6) = 
-3.04, p < 0.05], (males: M = 1819.95, SE =1507.63; females: M = -58.84, SE =132.14). 
 In the NAC, dose had a significant effect on p-ERK levels [F(3, 24) =4.17, p < 0.05]. P-ERK 
amounts increased significantly in the 0.125 mg/kg treatment in contrast to the 0.001 mg/kg drug group (p 
< 0.05). Meanwhile, dose and sex interacted in a two-way ANOVA in the AMYG [F(3, 24) = 3.11, p < 0.05], 
although the main effects of dose and sex were not significant, nor were independent samples t-tests 
assessing sex differences within drug conditions. Lastly, no main effects were found in a two-way ANOVA 
in the HIP. However, independent t-tests revealed sex differences in the 0.01 mg/kg treatment, where p-
ERK increased significantly more in males than females; [t(6) = -4.73, p < 0.01], (male: M = 57.74.55, SE 
=20.37; female: M =7.20, SE = 6.48).  
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Figure 19. Phospho-ERK protein levels (measured at 44/42 kDA) in the NAC (A) and CPU (B) of male (
) and female ( ) rats after EPM testing. Phosphorylated protein levels are expressed as a ratio to 
their respective total protein levels (normalized to α-tubulin, 55 kDA; SEM). Results are expressed as the 
percentage p-ERK vs saline. Outliers were removed when they were over 1.5 box-lengths outside of the 
I.Q. range for this measure. N = 4 per group. Two-way ANOVA followed by Tukeys’ post-hoc for overall 
dose comparisons: *p<0.05. Independent-samples t-tests to examine sex differences within doses. 
#p<0.05.  
A. mPFC. 
C. CPU. 
B. NAC          E. HIP 
D. AMYG 
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3.1.2c: phospho-CREB (Figure 20) 
A main effect of dose on p-CREB levels in the NAC was observed [F(3, 24) = 11.33, p < 0.0001]. NAC P-
CREB levels for rats treated with 0.125 mg/kg were significantly higher than in those treated with 0.001 
mg/kg, 0.01 mg/kg and 0.075 mg/kg CP55,940 (p < 0.01 for all conditions). Meanwhile, in the CPU, only 
sex had a significant main effect [F(1, 25) = 4.59, p < 0.05], although independent samples t-tests found no 
sex differences within individual drug treatments. Finally, no significant effects of dose or sex on p-CREB 
levels were observed in the mPFC, AMYG or HIP.   
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Figure 20. Phospho-CREB protein levels (measuresd at 46 kDA) in the NAC (A) and CPU (B) of male (
) and female ( ) rats after EPM testing. Phosphorylated protein levels are expressed as a ratio to 
their respective total protein levels (normalized to α-tubulin, 55 kDA; SEM). Results are expressed as the 
percentage p-CREB vs saline. Outliers were removed when they were over 1.5 box-lengths outside of the 
I.Q. range for this measure. N = 4 per group. Two-way ANOVA followed by Tukeys’ post-hoc for overall 
dose comparisons: **p<0.01. Independent-samples t-tests to examine sex differences within doses. 
                                                                      
 
B. NAC E. HIP 
D. AMYG A. mPFC
. 
C. CPU
. 
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3.1.2d: cFOS (Figure 21) 
In the NAC, significant main effects were found for dose [F(3, 24) =13.73, p < 0.001], sex [F(1, 24) = 9.30, p 
< 0.01], and the interaction between dose and sex [F(3, 24) = 6.37, p < 0.01]. Rats treated with 0.125 
mg/kg CP55,940 had significantly higher cFOS levels than those in the 0.001, 0.01 and 0.075 treatment 
groups (p < 0.001 for all comparisons). However, independent t-tests examining sex differences within 
dose conditions showed no significant differences.  
 Sex had a significant main effect on cFOS levels in the CPU [F(1, 24) = 4.87, p < 0.05]. However, 
no sex differences were observed within dose conditions. Likewise, a significant effect of sex was 
observed in the hippocampus [F(1, 27) = 9.01, p < 0.01]. Sex differences were observed in the 0.01 mg/kg 
treatment group [t(6) = 3.57, p < 0.05], in which cFOS amounts rose significantly more in females 
compared to males (females: M = 166.07, SE = 31.26; males: M = 41.56, SE = 15.54). To finish, no 
significant effects of dose or sex were found in the mPFC or AMYG. 
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Figure 21. CFOS protein levels (measured at 62 kDA) in the mPFC (A) NAC (B) CPU (C) AMYG (D) and 
HIP (E) of male ( ) and female ( ) rats after EPM testing. Protein levels are expressed as a ratio to 
their respective total protein levels (normalized to α-tubulin, 55 kDA; SEM). Results are expressed as the 
percentage cFOS vs saline. Outliers were removed when they were over 1.5 box-lengths outside of the 
I.Q. range for this measure. N = 4-5 per group. Two-way ANOVA followed by Tukeys’ post-hoc for overall 
dose comparisons: ***p<0.001. Independent-samples t-tests to examine sex differences within doses: 
#p<0.05.
A. mPFC 
E. HIP 
D. AMYG 
B. NAC 
C. CPU 
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3.1.3 Correlations between Behavioral and Biochemical Results 
3.1.3a Behavior and Thr34 phospho-DARPP-32  
DARPP-32 levels negatively correlated with the percent of open arm time among males treated with 
0.075 mg/kg and 0.001 mg/kg CP55,940 when assessing the CPU [r = -0.97, p < 0.05] and HIP [r = -0.96, 
p < 0.05]. Change in the percent of open arm entries was also accompanied by changes in DARPP-32 
levels in the NAC of females receiving 0.125 mg/kg CP55,940 [r = 0.97, p < 0.05] and the CPU of males 
in the 0.075 mg/kg dose condition [r = -0.98, p < 0.05]. HIP DARPP-32 levels decreased as the percent of 
open arm entries increased in males receiving 0.125 mg/kg CP55,940 [r = -0.99, p < 0.05]. The number of 
open arm end pokes increased with DARPP-32 in females given 0.01 mg/kg CP55,940 [r = 0.97, p < 
0.05]. Finally, the number of beam breaks negatively correlated with DARPP-32 levels in the CPU [r = -
0.96, p < 0.05] and HIP [r = -0.99, p < 0.01] of males treated with 0.01 mg/kg CP55,940, while males in 
the 0.125 mg/kg dose condition showed a positive correlation in the HIP [r = 0.98, p < 0.05]. See Table 7 
for a summary of all behavioral and biochemical correlations. 
 
3.1.3b Behavior phospho-CREB 
The percent of time spent in the open arms correlated with p-CREB levels in the CPU of males in the 0.01 
mg/kg drug group [r = 0.96, p < 0.05], the AMYG of females receiving 0.125 mg/kg CP55,940 [r = 0.97, p 
< 0.05] and the HIP of males in the 0.001 mg/kg treatment condition [r = -0.97, p < 0.05]. There was a 
significant correlation observed for the percent of open arm entries and p-CREB levels in the AMYG [r = 
0.99, p < 0.05] and HIP [r = -1.0, p < 0.05] of males treated with 0.075 mg/kg CP55,940, as well as in the 
AMYG of females given 0.125 mg/kg CP55,940 [r = 0.98, p < 0.05]. P-CREB correlated with the percent 
of open arm pokes at the 0.001 mg/kg dose for males in the mPFC [r = -0.99, p < 0.05] and HIP [r = -0.99, 
p < 0.01], and when administered 0.01 mg/kg CP55,940 in the mPFC [r = 0.97, p < 0.05] and NAC [r = -
0.99, p < 0.05]. The number of open arm end pokes demonstrated correlations with p-CREB levels in the 
NAC of males treated with 0.001 mg/kg CP55,490 [r = 0.97, p < 0.05] and the mPFC of males receiving 
0.125 mg/kg CP55,940 [r = 1.0, p < 0.01]. Lastly, females receiving 0.075 mg/kg CP55,940 showed a 
correlation between the number of beam breaks and mPFC p-CREB levels [r = -0.96, p < 0.05], as did the 
NAC of males in the 0.001mg/kg dose group [r = -0.99, p < 0.01]. 
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3.1.3c Behavior and phospho-ERK 
The percent of open arm entries correlated positively with changes in p-ERK in the NAC and HIP of 
males and females treated with 0.125 mg/kg CP55,940 respectively [r = 0.97, p < 0.05 for both]. There 
was also a positive correlation for males in the 0.01 mg/kg dose condition when assessing the CPU [r = 
0.97, p < 0.05]. Protein levels also varied significantly with the percent of open arm pokes for mPFC p-
ERK levels in females of the 0.075 mg/kg treatment condition [r = -0.98, p < 0.05] and the CPU of males 
receiving 0.125 mg/kg CP55,940 [r = -0.99, p < 0.05]. Open arm end pokes correlated with ERK only in 
the mPFC of females that received 0.125 mg/kg CP55,940 [r = 0.98, p < 0.05]. P-ERK levels correlated 
significantly with the number of beam breaks in the AMYG of females given 0.075 mg/kg CP55,40 [r = -
0.99, p < 0.05] and the HIP of males treated with 0.001 mg/kg CP55,940 [r = -0.97, p < 0.05] 
 
3.1.3d Behavior and cFOS 
A significant correlation was observed between the percent of open arm time and cFOS measures in the 
NAC of females treated with 0.01 mg/kg CP55,940 [r = -1.0, p < 0.05] and in the HIP of females receiving 
0.01 mg/kg of the cannabinoid [r = 0.97, p < 0.05]. In the NAC, there was also a significant relationship 
between percent of open arm entries and cFOS levels [r = -0.99, p < 0.05].  The percent of open arm 
pokes also showed a strong correlation with cFOS levels in the mPFC of males receiving 0.01 mg/kg 
CP55,940 [r = 0.99, p < 0.05] and the CPU of females in the 0.125 mg/kg dose condition [r = 0.96, p < 
0.05]. There were significant correlations between the number of open arm end pokes and cFOS in the 
0.01 mg/kg treatment condition for males in the CPU and AMYG [r = 0.96, p < 0.05 and r = -0.96, p < 0.05 
respectively]. In the HIP, significant correlations for males were observed in the 0.001 mg/kg condition [r = 
1.0, p < 0.05]. and for females in the 0.01 mg/kg dose [r = 0.99, p < 0.01]. At the highest dose condition of 
0.125 mg/kg, males showed a strong positive correlation between the number of beam breaks and cFOS 
levels in the NAC [r = 0.99, p < 0.05].     
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3.2 CB1R Antagonism Results  
3.2.1 Behavioral Results 
3.2.1a Anxiety Measures (Figure 22 & 23) 
A significant main effect of drug treatment on the percent of open arm time was found [F(3, 85) = 11.78, p < 
0.001]. V +V animals spent more time in the open arms than did animals of the RIM + V, V + CP and RIM 
+ CP groups (p < 0.001 for all comparisons) [See table 8 for a summary of all behavioral statistics].  
A significant effect of dose on the percent of open arm entries was observed [F(3, 85) = 8.06 p < 
0.001] in a two-way ANOVA. Animals in the V + V group had a higher percent of open arm entries than 
those in the RIM + V, V + CP and RIM + CP (p < 0.001, p < 0.01 and p < 0.001 respectively) drug 
conditions. In the RIM + CP treatment group, males had a significantly greater reduction in percent of 
open arm entries than did females; [t(20) = 2.54, p < 0.05], (males: M = 15.42, SE = 4.29; females: M = 
30.79, SE = 4.27).  
 
       
 
Figure 22. Sex (male ( ) vs female ( )) and dose effect of pretreatment with 3.0 mg/kg i.p. of CB1R-
antagonist rimonabant (RIM) followed by the 0.075 mg/kg i.p. of the CB1R- and CB2R-agonist CP55,940 
(CP) or vehicle (V) on classic anxiety measures in the EPM: A) percent open arm time and B) percent 
open arm entries in the EPM. Outliers were removed when they were over 1.5 box-lengths outside of the 
I.Q. range for these measures. N = 11-12 per group. Two-way ANOVA followed by Tukeys’ post-hoc for 
overall dose comparisons: **p<0.01, ***p<0.001. Independent-samples t-tests examined sex differences 
within doses: #p<0.05. 
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A significant main effect of dose was observed on percent of open arm pokes [F(3, 85) = 7.17, p < 
0.001]. V + V treated rats had a higher percent of open arm pokes than those in all drug conditions; RIM + 
V, V + CP and RIM + CP (p < 0.01, p < 0.05 and p < 0.001 respectively).  
In a two-way ANOVA, a significant effect of sex on number of pokes off ends of open arms was 
found [F(1, 85) = 23.32, p < 0.001]. In all drug treatments, males had a significantly greater number of open 
arm end pokes than did females: RIM + V [t(22) = -2.98, p < 0.01], (males: M = 22.75, SE = 2.87; 
females: M = 11.58, SE = 2.42); V + CP [t(21) = -2.81, p < 0.05], (males: M = 15.14, SE = 2.24; females: 
M = 7.5, SE = 1.61); RIM + CP [t(21) = -2.97, p < 0.01], (males: M = 18.10, SE = 2.68; females: M = 8.92, 
SE = 1.65).  
 
           
 
Figure 23. Effect of sex ((male ( ) vs female ( )) and pretreatment with 3.0 mg/kg i.p. of CB1R- 
antagonist rimonabant (RIM) followed by the 0.075 mg/kg i.p. of the CB1R- and CB2R-agonist CP55,940 
(CP) or vehicle (V) on A) percent of open arm pokes and B) number of open arm end pokes on the EPM. 
Outliers were removed when they were over 1.5 box-lengths outside of the I.Q. range for these 
measures. N = 9-11 per group. Two-way ANOVA followed by Tukeys’ post-hoc for overall dose 
comparisons: **p<0.01, ***p<0.001. Independent-samples t-tests to examine sex differences within 
doses: #p<0.05, ##p<0.01. 
 
3.2.1b Locomotor Measures (Figure 24) 
A significant main effect of dose on total arm entries was revealed in a two-way ANOVA [F(3, 87) = 5.35, p 
< 0.01]. The number of arm entries in the V + V group was significantly higher than in the V + CP and RIM 
+ CP drug treatment groups (p < 0.01 and p < 0.05 respectively). A significant main effect of sex was also 
A
. 
B
. 
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found [F(1, 87) = 6.416, p < 0.05]. RIM + CP treated males had fewer total arm entries than females of the 
same drug condition; [t(21) = 2.22, p < 0.05], (males: M = 60.15, SE = 5.55; females: M = 79.00, SE = 
6.35).  
Total distance traveled was also significantly altered by dose [F(3, 80) = 9.86, p < 0.001], where V + 
CP parameters were significantly lower than V + V, RIM + V and RIM + CP (p < 0.01, p < 0.001 and p < 
0.001 respectively) treatments. A significant main effect of sex was also observed [F(1, 80) = 10.06, p < 
0.01]. Across all conditions, males showed less distance traveled than females. This was significant in the 
V + V [t(14.80) = 2.46, p < 0.05], (male: M = 6665.68, SE = 131.12; female: M = 7491.58, SE = 308.59); 
RIM + V [t(18) = 2.31, p < 0.05], (male: M = 7232.30 SE = 180.59; female: M = 7792.80, SE = 162.74) 
and RIM + CP [t(19) = 4.26, p < 0.001], (males: M = 6525.80, SE = 302.43; females: M = 8161.36, SE = 
242.64) dose conditions.  
A main effect of dose [F(3, 85) = 6.87 p < 0.001] and sex [F(1, 85) = 8.94, p < 0.01], on the number 
of beam breaks was observed. The number of beam breaks was significantly lower in the V + CP dose 
compared to V +V, RIM + V and RIM + CP drug treatments (p < 0.001, p < 0.05 and p < 0.05 
respectively). V + V treated males had fewer beam breaks than V+ V treated females; [t(21) = 3.01, p < 
0.01], (males: M = 1229.68, SE = 34.93; females: M = 1374.36, SE = 32.79). In the RIM + CP treatment, 
males also had fewer beam breaks than females; [t(22) = 3.26, p < 0.01], (males: M = 1085.63, SE = 
50.37; females: M = 1328.50, SE = 54.93).  
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Figure 24. Sex (male ( ) vs female ( )) and dose effect of pretreatment with 3.0 mg/kg i.p. of CB1R- 
antagonist rimonabant (RIM) followed by the 0.075 mg/kg i.p. of the CB1R- and CB2R-agonist CP55,940 
(CP) or vehicle (V) on locomotor behavior in the EPM: A) total number of arm entries B) distance traveled 
in centimeters C) number of beam breaks. Outliers were removed when they were over 1.5 box-lengths 
outside of the I.Q. range for this measure. N = 8-11 per group. Two-way ANOVA followed by Tukeys’ 
post-hoc for overall dose comparisons: *Fp<0.05, **p<0.01, ***p<0.001. Independent-samples t-tests to 
examine sex differences within doses: #p<0.05, ##p<0.01, ###p< 0.001. 
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3.2.2 Biochemical Results  
3.2.2a: Thr34 phospho-DARPP-32 (Figure 25) 
In the mPFC, a dose [F(2, 24) = 5.36, p < 0.05], sex [F(1, 24) = 6.65, p < 0.05], and a dose x sex interaction 
[F(2, 24) = 5.75, p < 0.01] were all significant in a two-way ANOVA. DARPP-32 levels were significantly 
higher among V + CP females compared to R + V and R + CP treatment conditions (p < 0.05 for both 
comparisons). In the R + CP drug condition, DARPP-32 levels increased significantly more in females 
than males; [t(4.01) = 3.31, p < 0.05], (female: M = 122.05, SE = 78.54; male: M = 5.68, SE = 3.26) [See 
table 9 for a summary of all protein-related statistics]. 
 Sex had a significant effect on DARPP-32 levels in the NAC [F(1, 22) = 15.39, p < 0.01], DARPP-
32 levels increased significantly more in males than females in the R + V treatment; [t (8) = -2.96, p < 
0.05], (males: M = 53.03, SE = 19.02; females: M = 25.80, SE =7.78). DARPP-32 levels increased more 
in males than females of the R + CP dose as well; [t(3.47) = - 5.26, p < 0.01], (males: M = 37.39, SE = 
1.60; females: M = 21.76, SE = .72).  
 There were no effects observed in the two-way ANOVA for the AMYG. However, a sex difference 
was found in the RIM + V treatment, where males had significantly higher increases in DARPP-32 levels 
compared to females [t(3) = -2.28, p < 0.01], (males: M = 100.91, SE = 38.12; females: M = 13.47, SE 
=4.16).  
 Finally, in the CPU and HIP, no significant effects of drug or sex were observed, nor was there 
any significance in independent t-tests assessing sex differences within drug conditions.  
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Figure 25. Phospho-DARPP 32 (Thr34) protein levels (measured at 32 kDA) in the mPFC (A) NAC (B) 
CPU (C) AMYG (D) and HIP (E) of male ( ) and female ( ) rats after EPM testing. Phosphorylated 
protein levels are expressed as a ratio to their respective total protein levels (normalized to α-tubulin, 55 
kDA; SEM). Results are expressed as the percentage p-DARPP-32 vs saline. Outliers were removed 
when they were over 1.5 box-lengths outside of the I.Q. range for this measure. N = 4-5 per group. Two-
way ANOVA followed by Tukeys’ post-hoc for overall dose comparisons: *p<0.05. Independent-samples t-
tests to examine sex differences within doses: #p<0.05, ##p<0.01. 
D. AMYG     A. mPFC 
     B.   NAC 
C. CPU 
E. HIP 
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3.2.2b: phospho-ERK (Figure 26) 
A significant dose x sex interaction was observed in the mPFC [F(2, 22) = 3.51, p < 0.05]. In the V + CP 
dose condition, p-ERK increased significantly more in males than females; [t(4.08) = -3.18, p < 0.05], 
(male: M = 1120.55, SE =301.35; female: M =157.31, SE = 30.34). Meanwhile, in the HIP, no significance 
was found in a two-way ANOVA. However, an independent samples t-test demonstrated that V + CP 
treated males had significantly higher p-ERK levels than females (male: M = 8347.55, SE =1042.27; M = -
35.18, SE = 106.12), [t(6) = -6.28, p < 0.01]. Lastly, two way-ANOVAs in the NAC, CPU and AMYG 
showed no significance, nor did independent samples t-tests assessing sex differences within drug 
treatments.   
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Figure 26. Phospho-ERK protein levels (measured at 44/42 kDA) in the mPFC (A) NAC (B) CPU (C) AMYG (D) 
and HIP (E) of male ( ) and female ( ) rats after EPM testing. Phosphorylated protein levels are expressed 
as a ratio to their respective total protein levels (normalized to α-tubulin, 55 kDA; SEM). Results are expressed 
as the percentage p-ERK vs saline. Outliers were removed when they were over 1.5 box-lengths outside of the 
I.Q. range for this measure. N = 4-5 per group. Two-way ANOVA followed by Tukeys’ post-hoc for overall dose 
comparisons. Independent-samples t-tests to examine sex differences within doses: #p<0.05. 
B. NAC 
C. CPU 
E. HIP 
A. mPFC D. AMYG 
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3.2.2c: phospho-CREB (Figure 27) 
A dose x sex interaction was observed in the mPFC [F(2, 18) = 4.06, p < 0.05], although no main effect of 
dose or sex was observed.  No sex differences were found within individual dose conditions. Two-way 
ANOVAs in the NAC, CPU, AMYG and HIP were not significant, nor were independent samples t-tests 
assessing sex differences within individual drug conditions.  
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Figure 27. Phospho-CREB protein levels (measured at 46 kDA) in the mPFC (A) NAC (B) CPU (C) 
AMYG (D) and HIP (E) of male ( ) and female ( ) rats after EPM testing. Phosphorylated protein 
levels are expressed as a ratio to their respective total protein levels (normalized to α-tubulin, 55 kDA; 
SEM). Results are expressed as the percentage p-CREB vs saline. Outliers were removed when they 
were over 1.5 box-lengths outside of the I.Q. range for this measure. N = 4-6 per group. Two-way ANOVA 
followed by Tukeys’ post-hoc for overall dose comparisons. Independent-samples t-tests to examine sex 
differences within doses. 
A. mPFC D. AMYG 
E. HIP 
C. CPU 
B. NAC 
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3.2.2d: cFOS (Figure 28) 
Sex had a significant main effect on cFOS levels in the mPFC [F(1, 21) = 14.23, p < 0.01]. However, 
independent samples t-tests assessing sex differences within dose conditions failed to reach significance. 
A significant effect of sex was also found in the NAC [F(1, 19) = 15.89, p < 0.01. In particular, cFOS levels 
increased significantly more in males compared to females of the R + V treatment group; [t(6) = -7.88, p < 
0.0001], (male: M = 79.34, SE = 1.13; female: M = 52.49, SE = 3.22).  
 A sex and dose x sex interaction were observed in the CPU ([F(1, 19) = 109.12, p < 0.0001] and 
[F(2, 19) = 3.81, p < 0.05] respectively). CFOS levels increased in males while females showed a reduction 
in cFOS across all drug treatents: R + V [t(6) = -6.13, p < 0.01], (male: M = 114.17, SE = 20.76; female: M 
= -67.87, SE = 21.21); V + CP [t(7) = -24.61, p < 0.0001], (male: M = 73.42, SE = 2.33; female: M = -
25.45, SE = 3.45); R + CP [t(3.93) = -4.51, p < 0.05], (male: M = 80.02, SE = 24.68; female: M = -39.92, 
SE = 9.85). 
 Dose had a significant main effect in the AMYG [F(2, 18) = 3.94, p < 0.05], although independent 
samples t-tests within each drug condition examing sex differences were not significant. Finally, a two-
way ANOVA and independent samples t-tests showed no significance in the HIP.  
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Figure 28. CFOS protein levels (measured at 62 kDA) in the mPFC (A) NAC (B) CPU (C) AMYG (D) and HIP 
(E) of male ( ) and female ( ) rats after EPM testing. Protein levels are expressed as a ratio to their 
respective total protein levels (normalized to α-tubulin, 55 kDA; SEM). Results are expressed as the 
percentage cFOS vs saline. Outliers were removed when they were over 1.5 box-lengths outside of the I.Q. 
range for this measure. N = 4-5 per group. Two-way ANOVA followed by Tukeys’ post-hoc for overall dose 
comparisons. Independent-samples t-tests to examine sex differences within doses: #p<0.05, ##p<0.01, 
####p<0.0001.            
    C. CPU 
A. mPFC AMYG 
    B. NAC   E. HIP 
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3.2.3 Correlations between Behavioral and Biochemical Results 
3.2.3a Behavior and Thr34 phospho-DARPP-32  
A Pearson correlation coefficient was computed to assess the relationship between protein changes and 
behavioral changes in the CB1R antagonism study [Table10].  V + CP treated females showed a 
significant relationship between protein levels in the NAC and open arm time [r = 0.96, p < 0.05]. In the 
CPU males of the V + CP drug condition [r = -0.99, p < 0.05] also showed a strong relationship between 
brain and behavior measures.  Lastly, DARPP-32 levels in the HIPP were predictive of percent time spent 
in the open arms among females receiving V + CP [r = -0.99, p < 0.01]. DARPP-32 levels in the mPFC 
correlated negatively with the percent of open arm entries in females receiving RIM + CP [r = -1.0, p < 
0.01]. The relationship between open arm entries and HIP DARPP-32 levels were significant among 
females and males treated with V + CP [r = -0.99, p < 0.01 and r = -0.97, p < 0.05 respectively]. Males 
showed a significant correlation between DARPP-32 levels in the CPU and percent of open arm pokes 
when treated with RIM + CP [r = 0.97, p < 0.05], as did females receiving RIM + V in the AMYG [r = -0.89, 
p < 0.05] and V + CP in the HIP [r = -0.97, p < 0.05].  Open arm end pokes correlated with HIP DARPP-
32 levels for females in the V + CP treatment group [r = -0.95, p < 0.05]. For females in the V + CP dose 
condition, there was a significant correlation between DARPP-32 and the number of beam breaks in the 
NAC [r = 0.99, p < 0.01] and HIP [r = -0.96, p < 0.05]. Females in the RIM + CP drug group also 
demonstrated a correlation between CPU DARPP-32 and the total number of beam breaks [r = -0.99, p < 
0.05]. See table 10 to see the results for all behavioral and biochemical correlations for the CB1R 
antagonism study. 
 
3.2.3b Behavior and phospho-CREB 
Percent open arm time was significantly correlated with mPFC, CPU and HIP p-CREB levels for females 
in the V + CP [r = 0.95, p < 0.05; r = -1.0, p < 0.01 and r = -0.98, p < 0.05 respectively].  The percent of 
open arm entries correlated with changes in p-CREB levels in the mPFC and HIP of females given V + 
CP [r = 0.98, p < 0.05 and r = -0.98, p < 0.05 respectively]. In the CPU, there was a correlation at the V + 
CP [r = -0.99, p < 0.05] dose for females, while males showed a significant correlation in the RIM + V [r = 
-0.99, p < 0.05] and V + CP [r = -0.96, p < 0.05] drug conditions. The percent of open arm pokes was 
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significantly correlated with p-CREB levels in the CPU of males receiving V + CP [r = -0.99, p < 0.01] and 
HIP of females in the V + CP dose condition [r = -0.97, p < 0.05]. A strong correlation was observed 
between the number of open arm end pokes and p-CREB levels for females receiving RIM + V [r = -0.99, 
p < 0.05] and V + CP [r = -0.96, p < 0.05] in the HIP. Lastly, the number of beam breaks correlated 
negatively with p-CREB levels in the HIP of females treated with V + CP [r = -0.96, p < 0.05]. 
  
3.2.3c Behavior and phospho-ERK 
MPFC p-ERK levels correlated positively with the percent of time spent in the open arms among males of 
the RIM + CP drug treatment group [r = 0.91, p < 0.05]. The percentage of open arm entries negatively 
correlated with p-ERK levels in the mPFC of males treated with RIM + V [r = -0.97, p < 0.05].  Males in 
the RIM + CP treatment condition demonstrated a significant correlation between the number of open arm 
end pokes and p-ERK levels in the NAC [r = 0.99, p < 0.05].   For the number of beam breaks, a 
correlation was observed in males that were in the V + CP group and changes in p-ERK levels in the 
AMYG [r = -0.99, p < 0.05].  
 
3.2.3d Behavior and cFOS 
A strong negative correlation between the percent of open arm entries and cFOS levels in the AMYG 
were observed among females dosed with RIM + V [r = -0.99, p < 0.05] and V + CP [r = -0.97, p < 0.05]. 
Males given V + CP also showed a strong negative correlation [r = -0.97, p < 0.05]. The number of beam 
breaks also correlated with NAC cFOS of males receiving V + CP [r = 1.0, p < 0.05]. 
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VI. DISCUSSION 
In experiment one, our results agreed with previous studies showing a bi-phasic, dose-dependent 
behavioral effect of cannabinoids (in our case CP55,940) in male rodents on the EPM (Rubino et al., 
2008; Braida et al., 2007; Rubino et al., 2007; Schramm-Saptya et al., 2007; Marco et al., 2004; Marin et 
al., 2003; Arevalo et al., 2001; Onaivi et al., 1990). Our females on the other hand, showed a dose-
dependent increase in anxiety, contrary to our hypothesis that they would have a more robust version of 
the biphasic effects seen in males. Both sexes failed to maintain dose-dependent effects seen at 0.01, 
0.001 and 0.075 mg/kg doses at the 0.125 mg/kg dose. We suspect that 0.125 mg/kg of CP55,940 
reduces locomotor activity so profoundly that any changes in anxiety are masked; this agrees with other 
studies showing that high doses of cannabinoids can inhibit ambulation and locomotion (Craft et al., 2012; 
Jarbe et al., 2002; Tseng and Craft, 2001; McGregor et al., 1996). In terms of locomotor activity, our 
females demonstrated higher levels of locomotor activity than males, irrespective of dose, as has been 
observed previously (Craft et al., 2012). Finally, our use of two relatively novel dependent measures has 
encouraged us to continue utilizing these tools in the future. Our two new measures were percent open 
arm pokes and number of open arm end pokes. The latter appeared in a previous study by Cruz et al., 
1994 under the term “end-exploring”. These measures appear to be inverses or compliments of the 
classical dependent measures on the elevated plus maze. For example, as the classic measures showed 
reductions (and thus an anxiogenic profile) at 0.01 and 0.075 mg/kg, the number of pokes off the ends of 
the open arms increased. We noticed that females had higher percent of open arm pokes in all drug 
conditions except 0.125 mg/kg, where males had a far higher rate than females. This rise among males 
corresponded with a reduction in male locomotor and classic anxiety measures, and we postulate that the 
reduction in locomotion that impacted males so profoundly at this dose, caused them to increase open 
arm pokes as an alternative mean of exploration. We will therefore use these novel anxiety measures in 
future study and encourage other researchers to try it as well.   
We wanted to know the role of CB1Rs in the effects of CP55,940 seen during experiment one. In 
a follow-up study, we gave animals the CB1R reverse agonist rimonabant before 0.075 mg/kg CP55,940 
and tested the animals on the EPM. We used 0.075 mg/kg CP55,940 because this dose caused the most 
anxiogenic response in our animals in experiment one. As evidence suggests that rimonabant may itself 
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cause anxiety-like behaviors (Jarbe et al., 2006; Griebel et al., 2005; Jarbe et al., 2002; Arevalo et al., 
2001), we additionally looked at rimonabant and CP55,940 treatment alone. Rimonabant alone caused a 
significant increase in anxiety-like behavior for both sexes, in support of previous findings (Jarbe et al., 
2006; Griebel et al., 2005; Jarbe et al., 2002; Arevalo et al., 2001).  
We chose to use 3.0 mg/kg rimonabant with the hope that it would be like our cannabinoid, and 
have a bi-phasic effect on our animals. This hypothesis was derived from contradictions seen in previous 
studies. There were studies showing that this dose blocked the anxiogenic effects of cannabiniods on the 
elevated plus maze (Huang et al., 2010; Jarbe et al., 2006; Griebel et al., 2005, Rodgers et al., 2003; 
Jarbe et al., 2002; Arevalo et al., 2001), while other studies found an anxiogenic impact of this dose on 
EPM behaviors (Bellocchio et al., 2013, Bortolato et al., 2006; Navarro et al., 1997). Our hypothesis that 
in our case 3.0 mg/kg of rimonabant would provide blockade of CP-induced anxiety behaviors and 
thereby be anxiolytic was generally unsupported.  Only females experienced some restoration in percent 
of open arm entries, while males manifested a reduction in this measure. In the RIM + CP group, both 
sexes failed to restore levels of percent open arm time to those seen in the control group, and had a 
further reduction in this measure compared to V + CP. Our results are therefore in agreement with 
previous literature indicative of 3.0 mg/kg rimonabant being unable to block CP55,940-induced changes, 
or being anxiogenic at the 3.0 m/kg dose (Bellocchio et al., 2013, Bortolato et al., 2006; Navarro et al., 
1997).   
The fact that females in our study responded with an increase in anxiety on one measure, and a 
decrease on another classic EPM measure, requires further study. Our mixed findings in females, with 
one classic measure showing successful anxiolytic effects while the other is anxiogenic, require further 
study and are supported by the findings of Craft et al., 2012. They found that THC antagonism via 
rimonabant in females was ten times more potent on nociceptive tests, it’s affinity for the CB1R was 0.5 to 
1 mol/kg higher, and was effective at differential time points post-injection compared to males (Craft et al., 
2012). Their findings in combination with ours urge for more research on the sex effects of the selective 
CB1R reverse agonist rimonabant.  Overall however, our results are in consensus with previous findings 
suggesting sex differences involving CB1Rs. These include sex differences in the effects of rimonabant 
(Craft et al., 2012) in CB1R density (Castelli et al., 2014), CB1R binding (Riebe et al., 2010), CB1R 
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numbers by brain region (Gonzalez et al., 2000; Rodriguez de Fonseca et al., 1994), and 2-AG, MAGL 
and FAAH levels in the amygdala (Krebs-Kraft et al., 2010).  
We also saw sex differences in one of our two relatively-novel anxiety measures. Following 
rimonabant and/or CP55,940, there was a stronger increase in number of pokes off ends of the open 
arms in males, who also had stronger reductions in classic anxiety measures at that dose than did 
females. In contrast, only females followed this pattern in regards to percent of open arm pokes. These 
new anxiety measures may ultimately be helpful in comprehending the specificity and nature of sex 
differences in the mood disorders and the effects of cannabinoids. We therefore strongly suggest other 
researchers include these variables in their EPM research as well. Lastly, dose and sex significantly 
impacted our locomotor measures, with rimonabant partially or fully restoring the locomotor reduction 
caused by CP55,940, as was the case in other studies (Craft et al., 2012; Jarbe et al., 2006 Arevalo et al., 
2001). In all significant assessments of sex differences within dose conditions, males had significantly 
lower locomotor activity than females, which agrees with previous findings from Craft et al., 2012. 
Rimonabant alone (RIM + V) caused a reduction in our locomotor measures (Jarbe et al., 2006; Jarbe et 
al., 2002). 
Our two experiments show sex differences in the effects of CP55,940 and/or rimonabant on 
anxiety-related behavioral and biochemical measures.  In the DRC, we replicated some of the bi-phasic 
behavioral effects of cannabinoids previously seen in males (Rubino et al., 2008; Braida et al. 2007; 
Rubino et al., 2007; Schramm-Saptya et al., 2007; Marco et al., 2004; Marin et al., 2003; Arevalo et al., 
2001; Onaivi et al., 1990), whereas our females had a dose-dependent increase in anxiety. Given that 
CP55,940 is approximately 30 times more potent than THC (Little et al., 1988), it may be that we simply 
have not identified the range of doses that would elicit an anxiolytic effect of CP55,940 in females yet.  
Similarly, we postulate that a higher dose of our antagonist rimonabant, such as 5.0 mg/kg, may have 
been needed for more effective blockade of a cannabinoid agonist as potent as CP55,940.  It may be that 
some of the discrepancies between our findings and of the literature involved not having completed a 
DRC for CP55,940 and rimonabant in varying dose combinations.  Assessment of THC, or THC and CBD 
in varying dose combinations in comparison to the effects of CP55,940 and perhaps with rimonabant 
blockade, would all be needed to clarify whether a dose-dependent biphasic behavioral effect exists for 
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female rats on the EPM. To gain further information about anxiety levels, we will also measure changes in 
corticosterone levels, a glucocorticoid released by the adrenal cortex during stress response in future 
studies.  In sum, there are many additional measures that we would like to explore in future study that 
pertain to cannabinoids, sex differences and anxiety.   
The sex differences observed here in the effects of cananbinoids may be due to a number of 
differences between the sexes, including differences in fat levels and distribution.  Cannabinoids are 
lipophilic molecules which are attracted to fat cells, and in animals with higher numbers of such cells, 
cannabinoids will sit in these tissues and have longer-lasting but slower-acting effects than they would 
otherwise (Hill & Gorzalka, 2009).  In humans, fat metabolism and distribution and energy expenditure 
differ between the sexes (Davis-Takacs, 2013).  Females have more fat storage in their abdomen and 
thighs and more subcutaneous fat than do men (Power, 2008).  Female rats similarly have higher 
subcutaneous fat levels than do their male counterparts due to differences in estrogen and progesterone 
levels (Pedersen et al., 2004). Estrogen has also been implicated in maintaining healthy body weight in 
female rodents (Hong et al., 2009).  Thus, estrogen levels and body-fat distribution in rodents is a useful 
anaolog to that of humans, and is likely an important contributer to sex differences in the effects of 
cannabinoids in both humans and rodents.   
 Because rodents tend to avoid areas of higher luminance, increased illumination of testing 
conditions can increase anxiety in the animals at baseline (Kalueff and Tuohimaa, 2005). We sought to 
minimize baseline anxiety levels in our rodents by using low-light conditions (150 lux).  Our intent was to 
produce more robust anxiety-related effects in our study by doing so. However, this choice may have 
caused the reduction in anxiolytic effects observed in our study compared to our hypothesis.  Griebel et 
al., 1993 found that an increase of the level of illuminance was followed by a decrease of all behavioural 
parameters on the EPM.  Reducing anxiety-like behavior at baseline via low-light conditions may have 
reduced the ability of the two low doses of CP55,940 to exert anxiolytic effects.  In fact, a previous study 
found that the FAAH inhibitor URB597 was anxiogenic in rats which had experienced low-light testing 
conditions but was anxiolytic when testing procedures were under bright light conditions. These effects 
were mediated by CB1R as AM251 abolished the anxiolytic effects of URB597 (Haller et al., 2009).  The 
role of CB1R in the context-dependent effects of cannabinoids – particularly the role of light, was further 
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substantiated by another study that demonstrated that CB1R-KO mice but not WT mice showed 
increased anxiety-like behavior under high light conditions (Haller et al., 2004). We wonder if there may 
have also been a sex difference in the light-dependent anxiety effects of CP55,940 in our studies and 
would like to pursue this line of inquiry in further research.  Another recent study showed that sensitivity to 
illumination is age-dependent and is seen in adult rather than adolescent animals (Albani et al., 2015). 
Given that CB1R development occurs more quickly in females, shows differential brain region density 
between the sexes and appears to mediate the context-dependent effects of cannabinoids, we would 
further like to explore sex differences in the age- and context-dependent anxiety-effects of cannabinoids.  
Finally, given the sensitive, bi-phasic nature of cannabinoids, we suggest that researchers be more 
explicit in regards to luminance in their testing room, as this has frequently been linked to differences in 
the effects of cannabinoids (Albani et al., 2015; Haller et al., 2009; Kalueff and Tuohimaa, 2005; Haller et 
al., 2004; Genn et al., 2004; Griebel et al., 1993).  
Also notable is that in our studies we were unable to reverse the light:dark cycle, and had to test 
the animals during the light phase of their day when they would otherwise have slept, which may have 
also influenced the outcome of our studies. In a recent study, rats showed more anxiolytic behavior when 
tested between 8 h and 12 h than when performed between 14 h and 17 h, which suggests that time of 
testing during the cycle can also impact anxiety measures (Albani et al., 2015). Previous literature on 
cannabinoids and anxiety are mixed, with one on a reverse light:dark cycle (Arevalo et al., 2001), others 
maintaining standard light conditions as we did (Griebel et al., 2005; Rodgers et al., 2003; Navarro et al., 
1997) and others that do not specify (Bellocchio et al., 2013; Bortolato et al., 2006; Patel and Hillard, 
2006).  We believe that systematic assessment of the influence of time of testing during the light:dark 
cycle requires further study and are interested in assessing its’ impact on the sex-dependent anxiety 
effects of cannabinoids.  Furthermore, we posit that information on the light:dark cycle be a required 
disclosure in the methods sections of all cannabinoid research manuscripts for greater replicability and 
explanatory understanding of findings.  
 Thr34 phospho-DARPP-32 was significantly impacted by dose in the nucleus accumbens and 
caudate putamen, with post-hoc analysis revealing that 0.125 mg/kg differed significantly from all other 
doses. Our hypothesis that both low and high doses of CP55,940 would increase p-DARPP-32(Thr34) 
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levels was supported by our findings and was in accord with previous literature (Polissidis, 2010; 
Borgkvist et al., 2008; Chiang and Chen, 2007; Andersson et al., 2005). We had further postulated that 
females would manifest a larger rise in p-DARPP-32 levels than males, which was also affirmed by our 
findings and concurred with previous research showing that female rodents are more sensitive to the 
effects of cannabinoids than males (Craft et al., 2012; Cha et al., 2010; Gorzalka et al., 2010; Wiley et al., 
2007; Fattore et al., 2007; Tseng et al., 2004; Wiley, 2003; Romero et al., 2002; Tseng and Craft, 2001). 
The only dose condition that did not follow this trend was 0.125 mg/kg, a dose which failed to continue the 
dose-dependent anxiogenic behavioral effects of the 0.01 and 0.075 mg/kg doses of CP55,940 in both 
sexes (and 0.001 mg/kg dose for females). 0.125 mg/kg CP55,940 most likely did not cause the dose-
dependent anxiogenic response anticipated in males due to its’ inhibition of motor behavior which was 
accompanied by increases in caudate putamen p-DARPP-32 levels, as has been observed previously 
(Andersson, 2005). In females, it remains unclear as to how this dose impacts locomotion and/or anxiety-
like behavior. We believe that 0.125 mg/kg CP55,940 is not an effective dose for assessing the anxiety-
like effects of CP55,940. Overall, CP55,940 had a more significant impact on anxiety-like behavior than 
locomotion in females, while in males, CP55,940 altered behavior and locomotion in a more 
corresponding and therefore significant manner, all of which is supported by our findings with p-DARPP-
32(Thr34).  
 In the V + CP condition of experiment two, there was an increase in p-DARPP-32 levels caused 
by CP55,940 in four brain areas (all but the striatum), which was significant in the prefrontal cortex and 
nucleus accumbens. There was a sex difference, as females showed successful blockade of the effects 
of CP55,950 by rimonabant in the former brain region, and males in the latter.  These CP55,940-induced 
increases in p-DARPP-32 levels in the V + CP dose were accompanied by significant reductions in 
locomotor measures. Accordingly, the RIM + CP group demonstrated successful blockade of CB1R-
mediated increases in p-DARPP-32 in those four brain regions, and restoration of the locomotor 
behaviors measured.  These results of CB1R-mediation of the effects of CP55,940 are in accord with 
previous studies (Polissidis, 2010; Borgkvist et al., 2008; Chiang and Chen, 2007).  
There were sex differences in the effects of CP55,9540 on p-ERK levels.  Among female rodents, 
dose-dependent increases in p-ERK levels from 0.001, 0.01 to 0.075 mg/kg were matched by reductions 
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in classic anxiety measures on the EPM. Accordingly, the modest increase in p-ERK levels at 0.125 
mg/kg was paired to a modest reduction in open arm behavior. 
Changes in p-ERK expression may have underlied the largest reduction in open arm behaviors among 
both sexes which was at 0.075 mg/kg, as males and females showed their highest increase in p-ERK 
levels at this dose across multiple brain regions. In males, there was a significant rise in p-ERK levels at 
0.125 mg/kg in the nucleus accumbens, caudate putamen and amygdala that corresponded with 
significant motor inhibition and an increase in the percent of open arm pokes on the EPM. These results 
are collectively in agreement with previous research correlating increased ERK levels to increased 
anxiety-like behavior on the EPM (Qi et al., 2009; Qi et al., 2008; Todorovic et al., 2008; Tronson et al., 
2008; Qi et al., 2006).  
In experiment two, our p-ERK results were in accord with previous research linking increased 
ERK levels to increased anxiety-like behavior on the EPM (Qi et al., 2009; Qi et al., 2008; Todorovic et 
al., 2008; Tronson et al., 2008; Qi et al., 2006), but we also saw sex differences.  In both the medial 
prefrontal cortex and hippocampus, males had significantly higher p-ERK levels than females in the V + 
CP drug condition, and males of the V + CP dose had very low open arm activity. There were also trends 
indicative of sex differences in the RIM + V drug condition in every brain region, and in three brain areas 
for the V + CP group. Despite these differences, most brain regions showed some reduction in p-ERK 
levels following rimonabant pretreatment in the RIM + CP group, although the brain regions in which 
these partial-restorations happened varied by sex. Our results support the broad theory that stimulation of 
CB1Rs effects ERK activity (Rubino et al., 2007; Rubino et al., 2004; Rubino et al., 2000; Valjent et al., 
2001), but require further study into sex differences in these effects. 
 Sex effects were also at play in our assessment of phosphorylated-CREB levels in experiment 
one. Levels of p-CREB were significantly altered by sex in the caudate putamen, where they dropped for 
females and increased for males at the 0.125 mg/kg dose. In the nucleus accumbens meanwhile, that 
same dose was significantly different from all others and underlied a significant main effect of dose. Our 
hypothesis that low and high doses of CP55,940 would be bi-phasic, and that a bi-phasic change in p-
CREB would contribute to this, was not supported, as no clear relationship emerged between p-CREB 
levels and EPM behaviors in our study. It was only at 0.075 mg/kg that reduced p-CREB levels for both 
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sexes matched their increase in anxiogenic behavior. These results therefore are in disagreement with 
previous research that suggests a clear relationship between anxiety-like behavior and p-CREB levels (Qi 
et al., 2009; Rubino et al., 2008a; Rubino et al., 2007; Pandey et al., 2005). However, the previous 
studies cited utilized different cannabinoids and injection methods than did we, which may account for the 
differences seen here. Nonetheless, further research into sex differences is in the effects of cannabinoids 
on anxiety-like behavior and the protein changes that cause those changes is required.   
 Previous research showed that increased anxiety correlates with reductions in p-CREB (Rubino 
et al., 2007; Barrot et al., 2005; Pandey et al., 2005; Barrot et al., 2002). For experiment two, we therefore 
had anticipated a decrease in p-CREB levels in V + CP dosing (0.075 mg/kg CP55,940 which had been 
anxiogenic) and some restoration of p-CREB levels in the RIM + CP group. This was only observed in p-
CREB levels in the nucleus accumbens for both sexes, although no significant effects were found. The 
opposite trend, with increases in p-CREB levels in the V + CP dose compared to RIM + CP was seen for 
both sexes in the amygdala and only males in the hippocampus, and was non-significant. Our results 
therefore did not support previous research showing that increased anxiety is accompanied by decreased 
p-CREB in the amygdala and hippocampus (Qi et al., 2009; Rubino et al., 2008a; Rubino et al., 2007). 
Those studies however, used THC or ERK inhibitors via microinjection in males only, which may account 
for the differences in results. We found only a significant dose*sex interaction impacting p-CREB levels in 
the medial prefrontal cortex. Finding changes to p-CREB only in the prefrontal cortex following 
cannabinoid treatment was in accord with the findings of Rubino et al., 2007.  In the prefrontal cortex, p-
CREB levels were most elevated for females in the RIM + V exposure, as was the case in the caudate 
putamen. Conversely, p-CREB was most elevated for males at this dose in the nucleus accumbens and 
caudate putamen. These increases corresponded to a mild anxiogenic response on the EPM, and further 
establish the need to complete more studies examining sex differences in the effects of cannabinoids – 
particulary rimonabant alone or incombination with a cannabinoid agonist, on anxiety-like behavior and 
the protein pathways underlying those behaviors.  
 Previous research in male rodents has linked anxiogenic behavior on the EPM to rises in cFOS 
(Ailing et al., 2009; Troakes and Ingram, 2009; Arnold et al., 2001), and anxiolytic behavior to reductions 
in cFOS (Rubino et al., 2007). Meanwhile, no correlation between female cFOS levels and EPM 
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behaviors has been established (Sayin et al., 2014). CP55,940 had a significant dose effect in the 
nucleus accumbens and there was a dose*sex interaction in the caudate putamen. Both findings are in 
accord with previous work showing that cannabinoids alter cFOS levels in those brain areas (Beiderbeck 
et al., 2012; Zarrindast et al., 2008; McGregor et al., 1998; Porcella, et al., 1998; Miyamoto et al., 1997; 
Miyamoto et al., 1996). We had robust sex differences in cFOS levels following CP55,940 administration. 
Sex had a significant main effect in the nucleus accumbens, caudate putamen and hippocampus. In the 
nucleus accumbens, 0.125 mg/kg caused a significant rise in cFOS compared to all other conditions, one 
which was more profound in males than females. CFOS levels decreased slightly by dose from 0.001, 
0.01 to 0.075 mg/kg among males in the caudate putamen, then were at roughly baseline levels at 0.125 
mg/kg CP55,940. Meanwhile, females showed a rise in cFOS levels at 0.001, a smaller increase at 0.01, 
their largest rise at 0.075 mg/kg, followed by a reduction in cFOS levels from baseline at 0.125 mg/kg. 
There was a comparable albeit non-significant trend in female prefrontal cFOS levels, where they again 
had a large reduction in cFOS only in the 0.125 mg/kg drug condition. The drop in cFOS levels in both 
brain areas may attribute in part for the partial restoration of open arm behavior at this dose in females, 
and is in accord with Rubino et al., 2007 who demonstrated that a decrease in cFOS correlates with a 
decrease in anxiety (Rubino et al., 2007). Males showed a steep rise in cFOS levels in the nucleus 
accumbens and a return to baseline in the caudate putamen, which may also account for their partial-
restoration of open arm activity at 0.125 mg/kg. These results suggest that sex differences exist in the 
protein pathways that underlie the anxiogenic effect of 0.125 mg/kg CP55,940, and that they require 
further study. Last, in the hippocampus, females expressed a significant increase in cFOS compared to 
males at the 0.01 mg/kg dose of CP55,940. Differential effects on cFOS levels may account in part for the 
sex differences we observed on the EPM, and require further research.  
Our hypothesis that rimonabant would block the CP55,940-induced increase in cFOS was not 
statistically supported in any of the brain regions examined. Cumulatively, we saw increases in cFOS 
levels in response to CP55,940 that were partially-reversed by SR14176 pretreatment in three of the five 
brain regions examined among males (medial prefrontal cortex, amygdala and hippocampus) and two of 
five brain regions examined among females (amygdala and hippocampus).  There was a significant main 
effect of dose only in the amygdala. Despite our lack of statistical significance, our trends were in 
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agreement with previous literature showing that a cannabinoid (THC) can cause increases in cFOS levels 
in male rodents (Rubino et al., 2007; Rubino et al., 2004; McGregor et al., 1998), which can be reversed 
by a CB1R antagonist (AM251; Rubino et al., 2007). There were significant sex differences in cFOS 
levels following cannabinoid agonist and antagonist exposure in the medial prefrontal cortex, nucleus 
accumbens, and caudate putamen. In the medial prefrontal cortex males showed the anticipated CB1R-
mediated increase in cFOS following CP55,940 administration which was reversed by rimonabant while 
females showed a drop in cFOS levels when given R + V or V + CP, and showed the highest decrease in 
cFOS when given RIM + CP. In the R + V condition of cFOS levels increased significantly in males 
compared to females in the nucleus accumbens, In the amgydala there was a significant dose-effect on 
cFOS levels, with RIM + CP blocking the increase in cFOS seen in the V + CP condition. The same trend 
was apparent but nonsignificant in the hippocampus. These supported our hypothesis that the CB1Rs are 
critical to increases in cFOS elicited by exogenous cannabinoids. Finally, cFOS levels in the striatum 
were significantly impacted by sex and there was a dose*sex interaction. Each drug condition had a 
significant sex difference, with a significant increase in cFOS among males while there was a significant 
decrease for females. Previous research showed that a variety of stressors increase cFOS levels and 
anxiety-like behavior in male rodents (Adamec et al., 2012; Troakes and Ingram, 2009; Ailing et al., 2009) 
and that cFOS regulates differential patterns of activation for different classes of stressors (Briski and 
Gillen, 2001; Dayas et al., 2001). The results in our females were to the contrary. We wonder if the dual 
stress of repeat injection had a differential, more substantial effect on female rodents that was mediated 
by cannabinoid exposure to produce the unexpected reductions in cFOS that we saw in the medial 
prefrontal cortex and caudate putamen in experiment two. Our hypothesis is derived from the work of 
Shepherd et al., 1992 and Blanchard et al., 1991 who reported that female rats consistently manifested 
greater defensiveness, particulary for common situations involving potential, as opposed to actual and 
present threats. On an anecdotal note, we also observed sex differences in the daily, two-week taming 
process: our female Wistars appeared to remain equally or grow more defensive over time, while males 
exhibited less defensive behavior over the course of taming. The unanticipated drop in cFOS levels 
requires further examination. Research on the effects of cannabinoids on cFOS activity in females, from 
additional doses of CP55,940 to investigating additional cannabionids is required.  
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As an additional exploratory analysis, we conducted Pearson’s correlations to quantify the 
interdependence of protein and behavioral changes [Table 7 and Table 10].  We initially analyzed the 
data irrespective of drug condition and quickly saw no significance, and therefore assessed the 
correlations within sex and drug group.  The fact that we observed neither a clear majority of non-
significance or significance across our correlations demonstrates that the relationship between brain and 
behavior is complex.  It is unfortunately not so simple as an increase in x protein induces change in y 
behavior. It is well established that a single behavioral output requires changes in numerous chemical 
cascades in the brain, and therefore unsurprising that we did not yield robust results (Alberts et al., 2002).  
However, our correlations do provide further evidence of the complex interaction between cannabinoids, 
sex and anxiety and provide additional evidence that these variables require further research.    
Ample evidence demonstrates that the dopaminergic system and endocannabinoid system 
heavily interact (Fattore et al., 2010a; Wise, 2009; Valentin and O’Doherty, 2009; Matyas et al., 2008; 
Marinelli et al., 2007; Succu et al., 2007; Riegel and Lupica, 2004; Melis et al., 2004). The 
endocannabinoid system modulates the firing of DA neurons, and is key to inducing certain DA-
dependent forms of synaptic plasticity (Melis and Pistis, 2007; Kauer and Malenka, 2007) such as long-
term depression (LTD; Thomas, Molenka and Bonci, 2000; Gerdeman and Lovinger, 2003; Mathur and 
Lovinger, 2012, Figure 9). The endocannabinoid system modulates the activity of DA neurons through 
regulating the phosphorylation of DARPP-32 via CB1R activation (Andersson et al., 2005; Carriba et al., 
2007; Glass and Felder, 1997; Jarrahian et al., 2004; Kearn et al., 2004; Borgkvist and Fisone, 2007). In 
future studies, we would like to examine activity of dopaminergic receptors (D1 and D2) and CB1R and 
CB2R activity. We would use DA agonists and antagonists in combination with our cannabinoid agonists 
and antagonists to explore sex differences in the anxiety-like effects of cannabinoids and explore the 
protein changes that correspond to the behavioral changes. We anticipate significant sex differences in 
DA and CB1R activity, as both of these are impacted by estrogen and the estrous cycle in females.  As 
estrogen is a modulator of dopamine release, it likely underlies some of the sex differences we observed 
in these studies.  In particular, the striking sex differences observed in CP55,940-induced changes to 
both DARPP-32 levels and locomotor behavior were likely a consequence estrogen levels in females.  
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Estrogen impacts DA levels, and the DARPP-32 protein has significant effects on movement via its’ 
integral role as an intermediary between the dopaminergic and cannabinoidergic systems  
Assessment of estrous and the role of androgens is the logical next-step in our research.  
Evidence indicates that the estrous cycle can impact HPA axis sensitivity (Viau & Meaney, 1991) anxiety 
behaviors (Palanza et al., 2001) and the effects of cannabinoids (Field & Tyrey, 1984; Craft and Leitl, 
2008; Wakley and Craft, 2011). Estradiol enhances both THC-induced nociception and WIN55,2-2-2 self-
administration in OVX female rats (Fattore et al., 2010b). Estrodiol can also modulate cannabinoid 
efficacy (Daniel et al., 2002; Winsauer et al., 2011; Craft & Leitl, 2008). We hypothesize that estradiol 
mediated the sex differences we observed in the present studies. 
Previous research also indicates sex differences in CB1R density by brain region (Castelli et al., 
2014) and in CB1R binding (Riebe et al., 2010), and receptor numbers by brain region, the latter 
fluctuating across the estrous cycle in females (Gonzalez et al., 2000; Rodriguez de Fonseca et al., 
1994).  Therefore, stage of the estrous cycle and CB1R density and binding may have also contributed to 
our results and will also be additional measures in future studies. We will follow-up on the present studies 
by using the same dose conditions but with the addition of a cohort of females that are exposed to a 
vaginal smear to correlate the estrous cycle with cannabinoid efficacy and anxiety behavior in females.  
Along the same lines, it will be equally informative to examine ovariectomised and orchidectomized rats in 
combination and absence with testosterone and estrogen supplement in the context of cannabinoids and 
anxiety.  We hypothesize that the sex differences we observed in the current studies will be absent in 
ovariectomised and orchidectomized rodents, which is a future study that we are currently planning. 
 Numerous physiological and biochemical sex differences likely underlie our findings of behavioral 
and biochemical sex differences in response to cannabinoids.   These differences include the higher 
levels of adipose tissue, differential CB1R binding and density by brain region, and differences from 
circulating estrogen and phase of estrous in females compared to males.  In our studies, we examined 
phosphorylation of proteins in the PKA cascade following acute drug exposure.  This was a reasonable 
first step in exploring the biochemical mechanisms of sex differences in the effects of cannabinoids 
because CBRs are coupled indirectly to phosphorylative activity which causes transient changes to 
phosphyorylation of PKA proteins (Jucker, 2002).  Ample evidence shows that acute drug treatment 
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exerts effects via alteration of protein phosphorylation systems (Lidow, 2000).  However, with chronic 
drug treatment, there is additional change in capacity of the enzymatic system rather than just the state of 
phosphorylation of protein substrate (Lajtha, 1984).  
We therefore anticipate that our sex difference findings will be more robust and be a better fit to 
our initial model of our hypothesis following chronic rather than acute exposure in follow-up experiments. 
The effects of differential fat tissue, CB1R binding and density and estrogen levels that likely triggered our 
current findings will all be more significant after long-term drug exposure, and previous research confirms 
this. Cannabinoids elicit differential behavioral and biochemical effects when administered acutely versus 
chronically (Patel et al., 2009; Rubino et al., 2004; Masur et al., 1971). There is also already evidence of 
sex differences in those longitudinal effects. For example, male and female adolescent rats given 0.4 
mg/kg CP55,940 chronically showed a sex difference, with females showing an anxiolytic profile 
compared to males (Mateos et al., 2011). Similarly, when male and female adolescent and adult rats 
were exposed to chronic THC, CB1Rs were downregulated for female adolescent rats for most brain 
regions examined and not for males (Burston et al., 2010). Lastly, among rodents of both sexes treated 
with chronic THC during adolescence, female rats which had received THC as adolescents showed a 
significant increase in time immobile in the forced swim test (FST) while male adults showed no drug 
effect in the FST (Rubino et al., 2007). Thus, we are interested in examining the effects of a chronic low 
versus high doses of CP55,940 or THC and rimonabant antagonism on anxiety-like behavior of male and 
female rats on the EPM, and of course to investigate the accompanying protein changes they entail.  
Chronic stress exposure can impact the anxiogenic or anxiolytic effect cannabinoids will have. 
Male rats that have been exposed to stress are more likely to respond to low and high doses of 
cannabinoids in a biphasic manner (Fokos and Panagis, 2010; Ganon-Elazar and Akirav, 2009; Hill and 
Gorzalka, 2004). We wonder if the combination of a longer taming period (2 weeks) and low-light testing 
conditions elicite low anxiety levels at baseline in our animals, which therefore failed to elicit as strong a 
biphasic response as anticipated in either sex.  In our upcoming assessments of sex differences in the 
effects of chronic cannabinoid exposure, we would include assessments of the effects of chronic stress 
exposure and age-dependent effects.  We would be interested in examining what happens to females 
exposed to chronic stress and given cannabinoids, given their higher propensity for a defensive response 
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(Shepherd et al., 1992; Blanchard et al., 1991) and differential response to chronic stress (Reich et al., 
2009; Wiley, 2003) and cannabinoids (Craft et al., 2012; Mateos et al., 2011; Wiley et al., 2011a; Burston 
et al., 2010; Gorzalka et al., 2010; Rubino et al., 2008; Fattore et al., 2007; Tseng et al., 2004; Romero et 
al., 2002).  By adding controlled chronic stress exposure to our next study, we hope to elicit the biphasic 
effect of cannabinoids in females which has proven elusive thus far.  
Abundant evidence reveals that cannabinoids evoke age-specific effects (Wiley et al., 2011b; 
Schneider et al., 2008; Cha et al., 2007; O’Shea et al., 2004). Albani et al. recently demonstrated age-
related differences in anxiety-like behavior on the EPM during the late postnatal period in rats when 
tested without drug (2015). Adult animals show a significantly greater anxiogenic response to acute THC 
than do adolescent animals, although this has been studied only in males (Schramm-Sapyta et al., 2007). 
Furthermore, THC-induced sex-differences in desensitization and down-regulation of CB1R are found in 
adolescents but not adult rats (Burston et al., 2010). Based upon the literature above, we hypothesize 
that we may find more anxiolytic responses to cannabinoids among juvenile females in support of our 
initial hypothesis and model as opposed to our present study in adults. We will explore this hypothesis in 
an upcoming study.   
Cannabinoids are not just biphasic, they are also context depenent. Therefore, a plethora of 
variables can impact the biphasic nature of cannabinoids. Stress levels of the animals before drug 
treatment can have a substantial effect on wether a given dose of a cannabinoid will be anxiolytic or 
anxiogenic (Hill et al., 2012; Hill et al., 2010a; Fokos and Panagis, 2010; Hill et al., 2009; Ganon-Elazar 
and Akirav, 2009; Hill et al., 2008; Hill et al., 2010b; Patel et al., 2009; Rademacher et al., 2008; Patel et 
al., 2005; Hill et al., 2005; Patel et al., 2004; Hill and Gorzalka, 2004). As such, there appear to be a 
number of methodological varaibles that can impact stress levels of rodent subjects and thereby 
performance in behavioral tasks. For example, the lighting over the elevated plus maze or other 
behavioral testing apparatus can significantly impact results (Albani et al., 2015; Haller et al., 2009; 
Kalueff and Tuohimaa, 2005; Haller et al., 2004; Genn et al., 2004; Griebel et al., 1993). Furthermore, it 
was recently reported that exposure to male but not female researchers produces stress in rodents which 
skews behavioral results (Sorge et al., 2014). We suggest that researchers conducting studies with 
cannabinoids provide further specificity in their methods section, such that they control for and include 
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information about the sex of the researchers working with the rodents, specify the illumination level over 
the testing apparatus and when testing occurred in the light:dark cycle. This would make replicability in an 
already complex subdiscipline far more attainable.  In our case, the lead author who tamed and tested the 
animals is female, but a male colleague sacrificed the animals, and our illumination over the EPM was 
~150 lux. In future studies, we will be sure to employ only female researchers in completion of anxiety 
experiments to control for the confound of sex of the researchers and may make lighting an independent 
variable in a follow-up study.     
Our results from the DRC lead us to hypothesize that there may be a smaller range of doses 
which are anxiolytic for females versus those for males. If this is the case, it will have important 
implications in the clinical setting, particularly right now.  At present, the ease of cannabis access is 
increasing with its’ legalization while drug use among women is increasing (Greenfield et al., 2010).  
Furthermore, new evidence is mounting showing that vulnerability to drug abuse, rate of escalation and 
difficulty to quit cannabis is greater among women than men (Kelly et al., 2006; Gunter et al., 2006; 
Becker and Hu, 2008; Hernandez-Avila et al., 2004; Copersino et al., 2010; Levin et al., 2010; 
Hernandez-Avila et al., 2004). To make things worse, women are significantly more likely to have an 
anxiety disorder than are men (McClean et al., 2011; Bruce et al., 2005; Kessler et al., 1995; Kessler et 
al., 1994), and individuals with an anxiety disorder are 2-3 times more likely than the general populace to 
have a substance use disorder (Kessler et al., 1994). Thus, if our current findings from experiment one 
are supported by later research, and evidence suggests that for women the anxiolytic benefits of 
cannabinoids are found in a smaller range of doses than are the anxiogenic effects, this must be 
elucidated as quickly as possible. Women suffering from or with family histories of mood disorders would 
need to be made aware that cannabinoid use may potentiate pre-existing or induce anxiety disorders.  
This additionally has relevance in the possible therapeutic efficacy of cannabinoids.  Cannabinoids may 
be useful in the treatment of pain disorders and epilepsy for example, but if a significantly increased risk 
of anxiety or depression as a side effect for female use exists, we need to elucidate this as soon as 
possible.  
In experiment two, pretreatment with rimonabant revealed sex differences in CB1R mediation of 
the effects of CP55,940. Our findings concur with a study showing that THC antagonism via rimonabant 
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in females is ten times more potent on nociceptive tests, its’ affinity for the CB1R is 0.5 to 1 mol/kg higher, 
and is effective at differential time points post-injection compared to males (Craft et al., 2012). Our work is 
also in agreement with research showing sex differences in CB1R binding (Riebe et al., 2010), and 
receptor numbers by brain region, the latter fluctuating across the estrous cycle in females (Gonzalez et 
al., 2000; Rodriguez de Fonseca et al., 1994), and work finding that cycling female rats have significantly 
lower CB1R density in the prefrontal cortex and amygdala than male and OVX females (Castelli et al., 
2014). There is also evidence that levels of MAGL and FAAH in the amygdala are all higher in females 
than males (Krebs-Kraft et al., 2010). All this data collectively highlight the need for more research on the 
biochemical underpinnings and behavioral effects of cannabinoids on females.  This is particularly 
important now, when cananbinoids are increasingly easy to access and increasing evidence shows that 
women are more vulnerable to experiencing negative outcomes from cannabis use (Kelly et al., 2006; 
Gunter et al., 2006; Becker and Hu, 2008; Hernandez-Avila et al., 2004; Copersino et al., 2010; Levin et 
al., 2010). 
Finally, we found sex differences in the effects cannabinoid treatment on p-DARPP32(Thr34), p-
ERK, p-CREB and cFOS. These proteins are part of a protein cascade implicated in anxiety and drug 
abuse. We assessed five brain areas per protein, and completed a two-way ANOVA comparing main 
effects of sex, dose, and a dose*sex interaction for each brain area per protein. Therefore, we completed 
twenty two-way ANOVAs per study. Of the twenty analyses in experiment one: four yielded a significant 
main effect of dose, seven had a main effect of sex, four significant independent samples t-tests 
confirming a sex difference within a given dose, and there were also four dose*sex interactions. In 
experiment two, of these twenty analyses: three showed a main effect of dose, five a main effect of sex, 
nine independent samples t-tests were significant which confirmed sex differences within particular dose 
conditions, and there were five dose*sex interactions. Many of the changes in protein levels of females in 
our study could not have been anticpated based upon previous literature in male rodents, which 
necessitates a substantial amount of additional research, and is in accord with other work indicating such 
(Craft et al., 2013, Craft et al., 2012). Clarifying how cannabinoids alter the PKA pathway in females 
differentially from males is the first critical step to creating much-needed gender-based dosing 
recommendations and drug interventions for cannabinoids. Currently, gender-based drug recovery 
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models for women are limited and relatively novel, but show promising preliminary results (Najavits, 2009, 
Diamond et al., 2002).  Infact, the only prescription drug that currently has sex-specific differences in dose 
recommendations is Ambien.  However, the sex differences research here and others like it suggest that 
future progress in medicinal efficacy will be found through gender-based therapeutics. Therefore, we can 
envision that the current results may help lay the groundwork for cannabinoid cocktails prescribed 
specifically for and to women to help alleviate and decrease the negative effects of cannabinoids that are 
specific to women.  Furthermore, we hope this research contributes to an increase in gender-based drug 
research and recommendations in the medical field overall.  
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V. ABBREVIATIONS 
2-AG: 2-arachidonoylglycerol 
5-HT: serotonin  
A2A: adenosine A2A receptor  
AC: adenylyl cyclase 
AcbC: nucleus accumbens core 
AcbSh: nucleus accumbens shell 
ACTH: adrenocorticotropic hormone 
AEA: N-arachidonoylethanolamine (anandamide)  
α-tubulin: alpha-tubulin 
AM251: N-(piperidin-1-yl)-5-(4-iodo-phenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbox-amide 
AMYG: amygdala 
ANOVA: analysis of variance 
BLA: basolateral amygdala 
BDNF: brain-derived neurotrophic factor 
BNST: bed nucleus of the stria terminalis 
CA1: cornus ammonis; an area of the hippocampus 
CAMKII: Ca2+/calmodulin-dependent protein kinase II 
cAMP: cyclic adenosine monophosphate 
CBR: cannabinoid receptor  
CB1R: cannabinoid receptor type 1 
CB1R-KO: CBR type-1 knockout mouse 
CB2R: cannabinoid receptor type 2 
CBD: cannabidiol 
Cdk5:cyclin-dependent kinase 5 
CeA: central nucleus of the amygdala 
CNS: central nervous system 
CP55,940: (–)-cis-3-[2- hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol 
CPP: chlordiazepoxide 
CPU: caudate putamen 
CRE: cAMP response element 
CRH: corticotripin-releasing hormone 
CREB: cAMP responsive element binding protein 
CRH: corticotropin-releasing hormone 
D1: dopamine receptor type 1 
D2: dopamine receptor type 2 
DA: dopamine 
DAGL: diacylglycerol lipase  
DG: dentate gyrus in hippocampus 
DMH: dorsomedial hypothalamic nucleus 
EPM: elevated plus-maze 
ERK: extracellular signal-regulated kinase 
EXP1: experiment 1 
EXP2: experiment 2 
FAAH: fatty-acid amide hydrolase 
GABA: γ-aminobutyric acid 
GC: glucocorticoids 
GLU: glutamate 
HIP: hippocampus 
HF: high-light and familiar 
HPA: hypothalamic pituitary-adrenal 
LH: luteinizing hormone 
LF: lo-light and familiar 
L/D: light/dark 
LTD: long-term depression 
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LTP: long-term potentiation 
IP: intraperitonial 
MAGL: monoacyl-gyceral lipase 
MAPK: mitogen-activated protein kinase 
mPFC: medial prefrontal cortex 
mRNA: messenger ribonucleic acid 
NAC: nucleus accumbens 
NPY: neuropeptide Y 
NTS: nucleus tractus solitaries 
OF: open field paradigm 
OVX: ovariectomized rat 
PCR: Polymerase chain reaction 
PKA: protein kinase A 
PNC: parvocellular neuroendocrine cells 
PND: postnatal day 
PP-1: protein phosphatase 1 
PVN: paraventricular nucleus 
PVDF: Polyvinylidene difluoride 
Rimonabant: [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1- piperidinyl-1H-pyrazole-3-
carboxamide (SR141716; RIM) 
SI: social interaction test 
SNc: substantia nigra 
THC: Δ (9)-tetrahydrocannabinol  
TrkB: tropomyosin receptor kinase B 
VTA: ventral tegmental area 
WIN55,212-2: (11R)-2-methyl-11-[(morpholin-4-yl)methyl]-3-(naphthalene-1-carbonyl)-9-oxa-1-
azatricyclo[6.3.1.0⁴,¹²]dodeca-2,4(12),5,7-tetraene 
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